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Preface
This dissertation is a compilation of three projects centered on enhancing
the longevity of immune responses by tumor-reactive T cells. Chapter 3 of this
dissertation examines the synergy of T cell functional enhancement via patient
total body irradiation and the memory capacity of Tc17 cells. This work was
published in the June 2015 edition of Clinical Cancer Research. Chapter 4
investigates the durability of Th17 cells to preserve antitumor efficacy both during
in vitro expansion and after infusion. This work was published in the March 2017
edition of JCI Insight. Chapter 5 explores the potent enhancement of memory
phenotype and antitumor efficacy of T cells following in vitro PI3K blockade using
the small molecule inhibitor CAL-101. This work is in preparation for submission
by mid-summer 2017.
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JACOB STUART BOWERS. Generating Memory T cell Responses to Cancer:
Three Approaches Towards a Cure. (Under the direction of CHRYSTAL PAULOS).
Abstract
The development of immunotherapies over the last three decades has
dramatically improved treatment for late stage cancers. Among these therapies is
adoptive T cell therapy (ACT), which enriches and expands autologous tumorreactive T cells for reinfusion to the patient. ACT has exploited the power of T cells
to exert long-term immunity providing unprecedented responses, including
complete remissions and cures. Three major benefits of ACT have emerged since
the early trials: 1), ACT provides a window for preconditioning the patient. This
allows transferred T cells to engraft in large numbers, become functionally
enhanced, and be free of immunosuppressive pressure. 2), ACT allows for the
selection of T cells with superior antitumor qualities for treatment. 3), The ex vivo
expansion period allows for further manipulation of those T cells to enhance their
antitumor capacity. Also, an overarching theme in ACT is that complete and
durable responses are possible in patients who receive T cells capable of longterm memory responses. We examined the impact of each element of the ACT
regimen on the memory of T cells including how preconditioning influences
memory and function, the advantage of employing IL-17 producing CD4+ T cells
(Th17) cells with durable memory properties, and how to endow CD8+ T cells with
improved memory capacity through blockade of the PI3K pathway. We
discovered we can ex vivo prime T cells with IL-12 to mimic the potentiating effect
xi

of an activated innate immune system to improve the longevity of antitumor
immunity and reduce the dose of total body irradiation (TBI). We also report that
Th17 cells naturally express stem memory, which allows for expansion to high
numbers of durable effectors and long-lasting immunity against tumors. Finally,
peripheral T cells genetically redirected against tumors with chimeric antigen
receptors (CAR T cells) can be enhanced by pharmaceutical blockade of PI3K
endowing a durable memory phenotype that controls tumor after conventional CAR
T cells fail. Thus, this dissertation provides evidence that at each step in the ACT
protocol, T cells can be selected, or enhanced to exert powerful memory immunity
that translates into durable responses in patients with late stage malignancies.

xii

Chapter 1: Harnessing Memory T cells to Improve Cancer Immunotherapy

The challenge of metastatic disease
While early detection and improved surgical techniques have greatly
increased survival among patients with early stage/local cancers, gains against
metastatic disease have been slow across cancer sites. This is well represented
in patients with breast cancer, where early detection in stage 0 or 1 results in nearly
100% survival at 5 years. Yet, patients diagnosed with stage 4 breast cancer have
a 5 year survival rate of 22% (1). These rates translate into metastasis
representing 90% of breast cancer related deaths. Additionally, adjuvant
chemotherapy for localized breast cancer only prevents metastasis in about half
of the patients who receive it (2). In the case of liver cancer, patients diagnosed
with local disease have a 5 year survival rate of 30.5%, while the survival rate for
patients diagnosed with distant disease is 3.1% (3). Melanoma follows the same
trend with 90% survival at 10 years for stage 1 disease but only 10% survival at 10
years for stage 4 (4).
However, set against this bleak background, melanoma was also the
impetus and origin of a novel group of therapies which act through the immune
system (coined immunotherapies). These therapies are based on the theory that
NK cells, CD8+ T cells, and CD4+ T cells reconnoiter the body seeking out and
destroying newly transformed cells and preventing the outgrowth of tumors (5).
1

While still in its infancy, immunotherapy has already produced drastic increases in
both objective and complete responses in patients who suffer from late-stage
disease.

Immunotherapy for melanoma: a model for treating metastatic disease
For decades, the only approved treatment for metastatic melanoma was
dacarbazine, a typical chemotherapy which extended survival for patients by a
median of only 6.4 months (6). The past two decades have seen the development
and FDA approval of promising new immunotherapies for the treatment of latestage melanoma with marked improvement in outcomes. Table 1-01 summarizes
the objective and complete responses seen in recent trials of immunotherapies
against metastatic melanoma in comparison to dacarbazine chemotherapy.
The most successful immunotherapies to date are based on manipulating
tumor-reactive T cells. The earliest of these applied systemic treatment of the T
cell growth factor interleukin-2. As an early proof of concept, this treatment had
modest success in patients with renal carcinoma (7), and doubled the rate of
complete responses in patients with metastatic melanoma over dacarbazine (8).

2

Table 1-01. Treatment Response Rates in Patients with Metastatic Melanoma.

A summary of the therapeutic outcomes of current therapies for metastatic
melanoma including objective and complete responses based on the Response
Evaluation Criteria In Solid Tumors (RECIST) criteria.
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Checkpoint blockade takes the brakes off immunotherapy
More recently, new understandings of how T cells are negatively regulated
in the tumor led to the development of the checkpoint blockade antibodies antiCTLA-4 (Ipilimumab) and anti-PD-1 (Pembrolizumab and Nivolumab). These
therapies share the underlying goal of “removing the brakes” or inhibitory signals
that the T cells are receiving from the tumor microenvironment (9-11).
Soon after its discovery, Cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) was described as a negative regulator of T cell activation that directly
competed with CD28 for CD80 and CD86 on APCs (12). This led to in vivo studies
with monoclonal antibodies that prevented CTLA-4 binding and resulted in tumor
regression (13). More recent work suggests that not only does the antibody prevent
effector T cell inhibition, but also breaks immune tolerance by causing the
depletion of CTLA-4 expressing Tregs in the tumor (14). This therapy moved the
field forward by doubling objective responses in comparison to systemic IL-2 (15).
Programmed Death receptor 1 (PD-1) was originally discovered in T cells
undergoing apoptosis (16). It was eventually linked with T cell inhibition and
exhaustion in chronic viral infections (17, 18) and the tumor microenvironment (19).
This led to early trials of the anti-PD-1 monoclonal antibody Nivolumab in
melanoma, lung, colon and renal cancer with impressive outcomes (20). As single
agents, CTLA-4 and PD-1 blockade produce unprecedented objective responses.
But, in combination they have a particular therapeutic potency generating objective
responses in over half of patients (15). Because of the unprecedented levels of
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patient responses on checkpoint blockade therapy, anti-CTLA4 and anti-PDI
therapy are quickly becoming approved to treat multiple malignancies (21). These
findings in turn, have fueled excitement for immunotherapies within the oncology
community.

Adoptive cell therapy for cancer
The first generation of adoptive cell therapy (ACT) for metastatic melanoma
used peripheral lymphocytes grown in the presence of the patient’s tumor and IL2 termed “lymphokine activated killer cells” (22). This approach was followed by
the first trials with tumor infiltrating lymphocytes (TIL). In TIL therapy, T cells are
obtained directly from the patient’s tumor, and then in vitro selected for antitumor
function, and expanded to large numbers before reinfusion into the patient (23-26).
In these early TIL trials, 34% of patients achieved objective responses (25). Later
studies enhanced the power of TIL based therapies with the addition of
lymphodepleting regimens prior to adoptive T cell transfer. When patients received
a preparative regimen of chemotherapeutics or chemo-radiation prior to receiving
TIL and bolus IL-2 objective response rates rose to 54% (27). Since this time, a
minimum of partial myeloablation (removal of most peripheral and some central
hematopoietic cells) has been a staple in every ACT regimen.
While the objective response rates from ACT with chemo-radiation
preconditioning was similar to the results of combined checkpoint blockade therapy
(54% vs. 57.6%), ACT is distinct in yielding durable complete responses. Notably,
5

even 30 years since treatment, 24% of patients in the preconditioning plus ACT
trials still have complete responses; more than double the combined checkpoint
therapy (24% vs. 11.5%) (15, 27). Thus, while ACT is more cumbersome than
checkpoint blockade and not yet FDA approved for wide spread use, these clinical
findings highlight the unique potential of ACT for long-term control of aggressive
malignancies.

Enriching tumor-reactive T cells from the periphery
The tumor is an obvious first choice as a source of tumor-reactive T cells
for ACT, but there are apparent limitations. In the early TIL trials, complications
arose when T cells from some patients grew poorly or not at all. Additionally, not
all patients who received T cell transfer responded to therapy indicating that not all
TIL is equally potent (25). We know now that it is highly common for T cells within
the tumor to be exhausted, and this exhaustion is imprinted in the genetics of those
T cells (28). An additional complication is that TIL are not present in every cancer
type, but usually only appear in those cancers with higher mutational burden (29).
Thus, obtaining tumor-reactive T cells from the peripheral blood of patients
is an attractive concept. Early work that described circulating lymphocytes specific
for melanoma tumor antigens (30) led to different techniques for expanding
antigen-specific T cells including using antigen peptide presenting APCs (usually
autologous dendritic cells) (31), and nanoparticle artificial APCs (32). However,
clinical trials which used melanoma antigen-specific T cells expanded from
6

peripheral blood had similar rates of partial responses and complete remission as
those in the TIL trials. (33, 34). Thus, obtaining a tumor antigen-specific cell is not
enough, but successful treatment requires the expansion of tumor-reactive T cells
capable of long-lived immunity.

Endowing specificity through genetically engineering T cells
Methods to generate rather than enrich antigen specific T cells for ACT
include the genetic redirection of peripheral T cells to express either T cell
receptors (TCRs) (35-37) or chimeric antigen receptors (CARs) (38-41). The
benefit of genetic receptor redirection is it allows the selection of T cells capable
of exerting a potent and durable immune response (ie. not exhausted). However,
transgenic TCRs are still limited to HLA restriction making them not available for
every patient. Further complicating the problem, HLA restriction also requires that
a mutation occur within a peptide sequence that can be presented by MHC (42).
CARs bypass the requirement of MHC antigen presentation by fusing the
intracellular signaling domain of the TCR receptor complex (CD3), with the
antigen binding fragrment (Fab) of an antibody specific for a surface protein highly
expressed on a tumor (38). Thus, in an MHC-independent manner, a CAR-T cell
can recognize a tumor expressing the cognate protein in any patient with that
cancer (for instanced CD19+ blood malignancies). Additionally, CARs can now also
directly address the issue of improving the potency of the T cell, with the second
and third generation of CARs also containing the signaling domain of costimulatory
7

ligands (42). Different costimulatory signals (i.e. CD28 vs. ICOS vs. 4-1BB) endow
different metabolic, functional, and memory capacities in the cells, and thus T cells
can be engineered with a CAR that fits the goal of the therapy (43). Already, CART cells have proven very effective in clinical trials against lymphoma (39, 40) and
multiple CARs are being developed against common antigens in solid tumors
including mesothelin, fibroblast activating protein, and Muc-1 (38, 44, 45).
Yet, no matter whether tumor-reactive T cells are enriched or engineered
from TIL or peripheral blood, we and other cancer immunologists have identified
three major elements common for successful ACT therapy: 1) lymphodepletion of
the patient to break immunological tolerance and permit persistence of infused T
cells, 2) the quality and fitness of the T cell selected for therapy, and 3) the optimal
expansion of those T cells ex vivo to improve antigen specificity, function, and
memory. Additionally, evidence mounts that using a T cell for ACT with a less
differentiated phenotype improves outcomes through long-lived memory immune
responses (46-50). Preserving or inducing “memory” in tumor-reactive T cells
during ex vivo expansion is therefore an overarching goal of ACT preparation
(Figure 1-01).
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Figure 1-01. Improving ACT therapeutic outcomes by inducing memory.

Strategic enhancements of memory within each element of ACT to provide
long-lived antitumor immunity to patients.

9

The importance of memory: persistent and stronger antitumor responses
Immune memory was first recognized in the context of vaccines which were
able to endow long-lived (including life-long) protection against a pathogen (51).
The concept of memory within the adaptive immune system is rapidly evolving but
still contains at its core the concept of a B or T cell which persists after the initial
immune response and can mount repetitive responses against an antigen
throughout the host’s lifetime (52). T cell memory is also important in tumor
immunity as patients in ACT clinical trials whose transferred T cells persisted
longer and at higher numbers had better responses and outcomes than those with
fewer, short-lived T cells (53). Also, further studies found that persistent antitumor
immunity was carried out by tumor-reactive T cells with longer telomere length
which are maintained by self-renewing cells (54, 55). Thus, it appeared that certain
subsets of T cells were capable of self-renewal and were responsible for long-term
immune protection (56, 57).

The hallmark memory receptors CD62L and CCR7
Memory T cells were first described as two groups distinct from naïve T cells
and were defined by location, function and expression of the surface markers
CD62L and CCR7 (58). At the time, naïve T cells were known to use CD62L and
CCR7 receptors to enter lymphoid tissues. Yet, another subset of CD62L+ and
CCR7+ T cells was found in the lymphoid tissue which unlike naïve cells,
expressed CD45RO indicating prior antigen recognition. These cells were termed
10

central memory T cells because of their location in lymphoid tissue and their
memory-like capacity to rapidly activate APCs. Another subset mainly found in the
periphery expressed little CD62L and CCR7, but were highly functional with the
ability to rapidly produce inflammatory cytokines (such as IFN-) upon activation.
These were thus called effector memory T cells. Importantly, CD62L and CCR7
expression by naïve and central memory cells declined throughout culture, and
were never regained by effector memory cells. Therefore, this study also proposed
that at least in vitro, there was a continuum of differentiation from naïve to central
memory to effector memory to effector T cell. (58).
While the trajectory of in vivo development of memory and effector T cells
remains highly debated (59), studies in many ACT models corroborate the theory
that naïve cells give rise to central memory cells, followed by effector memory and
effector cells in vitro following activation (46, 48, 60, 61). Additionally, these studies
reveal a strong correlation between less differentiated memory T cells (CD62Lhi or
CCR7hi T cells) and better antitumor treatment outcome (50, 62), with loss of
antitumor efficacy associated with terminal effector differentiation (46-50). Thus,
strategies to limit T cell maturation and to preserve long-lived memory is a critical
goal in the field of cancer immunotherapy.

Stem memory T cells exert durable immune responses against tumor
The first report of stem cell-like T cells described a sub-population of
CD62L+ memory cells which also expressed Sca-1 on their surface. These cells
11

were able to generate all other memory and effector T cell subsets and prolong
GVHD (63). Further studies showed that these cells were a distinct memory subset
that actively signals through -catenin (64). Human T cells with the same active
Wnt signaling also gave rise to all other memory and effector lineages including
central memory and were dubbed stem memory T cells (Tscm) (60). Importantly,
when compared head-to-head with other memory subsets, stem memory T cells
exerted better control of tumor (60). Additionally, pharmaceutical inhibition of catenin degradation by GSK3 endowed T cells with the phenotype of Tscm cells.
These findings indicate that active Wnt signaling is not only an important indicator
of a less differentiated T cell, but may be an important driver of durable T cell
memory and superior antitumor potency.

Homeostatic gamma chain cytokines in T cell memory
IL-2, IL-7, and IL-15 belong to a family of cytokines whose receptors share
a common gamma chain. These cytokines also have shared function in promoting
the proliferation, preservation and persistence of T cells (and other cells like NK
cells). They are therefore often referred to as “homeostatic cytokines” for their
importance in maintaining these populations in the body (65).
Early clinical trials in cancer explored the role of IL-2 to enhance
endogenous tumor-reactive T cells. This therapy was successful at clearing tumor
in some patients but its effects on tumor growth was modest in most individuals (7,
8). In ACT, IL-2 is used to rapidly expand CD8+ T cells in vitro (22) and then further
12

boost CD8+ T cell proliferation after transfer through systemic administration (24,
25). Yet, IL-2 has limitations as it mediates substantial toxicities in some patients
(66), and terminally differentiates the CD8+ T cells (67) rendering the therapy less
effective (46).
Like IL-2, IL-15 also signals through both the IL-2 and gamma chain
receptors. Yet, IL-15 signaling supports the proliferation and preservation of
memory T cells and NK cells in vivo (68) and preserves a less differentiated
phenotype of T cells during in vitro expansion (69). It remains unclear why
signaling from IL-2 causes effector differentiation while IL-15 signaling through the
same two receptor chains uncouples proliferation and differentiation. The most
recent theory is that the differential signaling might be due to differences in ligandreceptor complex stability (70). Despite IL-15’s capacity to preserve memory
during proliferation, IL-2 is still commonly used to expand T cells for ACT clinical
trial protocols (33, 50, 71) mostly due to industry restraints (65).
Both naïve and central memory T cells express IL-7 receptor alpha (CD127)
and IL-7 is important in maintaining these cells in vivo (72). IL-7 also augments the
engraftment and prolonged antitumor activity of adoptively transferred IL-12
primed CD8+ T cells in mice (73). Under normal conditions, IL-7 is not a strong
proliferative signal. However, in cases of immune depletion, the per-cell signal of
IL-7 can be strong enough to induce proliferation even in antigen naïve T cells (74).
Additionally, even though IL-7 is a weak promoter of expansion, it can still
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contribute to a higher yield of cells by preventing apoptosis of memory cells, and
thus synergize with other gamma-chain signals (65, 75).
IL-21 induces many signals in T cells. IL-21 prevents terminal differentiation
of CD8+ T cells in a similar fashion to IL-15. This is in part due to blockade of
signaling downstream of IL-2 (76). In comparative studies, IL-21 supports the
antitumor immunity of CD8+ T cells better than the other homeostatic cytokines
(77). This does not appear to be due to a proliferative signal, although it can
synergize with other gamma-chain cytokines (75). Rather, IL-21 appears to
support the inflammatory nature of mature T cells, including acting as an
alternative pathway to induce inflammatory Th17 cells (77, 78).
The vital role of homeostatic cytokines to T cell growth and functional
augmentation makes them central to ACT protocols. Methods for increasing time
and strength of gamma-chain signals include the complexing of IL-2 with
antibodies (79) and IL-15 with its alpha receptor (80). Yet, one of the most potent
means of improving homeostatic cytokine availability for ACT is through host
preconditioning with either chemotherapy or irradiation. This has two major
benefits: 1) it induces homeostatic cytokine secretion (81) and 2), it removes
endogenous immune cells which would compete for these elevated cytokines (82).

The requirement for non-myeloablative preconditioning in ACT
Since the early TIL clinical trials, multiple studies have increased our
understanding of the importance of non-myeloablative preconditioning of patients
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prior to T cell transfusion. In these studies, three important benefits of
lymphodepletion are described: 1) the removal of immunosuppressive cells
including Tregs (83), 2) depletion of host immune cells which compete for
necessary homeostatic cytokines (known as cytokine sinks) (82), and 3) activation
of the innate immune system which in turn enhances the antitumor response of the
infused T cells (84). Thus, preconditioning improves the capacity of transferred
cells to maintain a memory response to the tumor and exert long-term control by
increasing the persistence of donor cells, as well as their function. The marked
increase in complete responses between TIL clinical trials which used
lymphodepleting

regimens

and

those

without

provides

evidence

that

preconditioning not only accentuates the initial immune responses, but also
increases the odds that T cell immunity will be long-lived (25, 27).

IL-12 signaling from irradiated dendritic cells enhances function and
prolongs the antitumor response of Tc17 cells
In chapter 1, we explored the role of preconditioning on the memory and
function of transferred CD8+ T cells. Since previous work found that ex vivo priming
of CD8+ T cells with IL-12 improved their persistence (73), we hypothesized that
IL-12 signaling following TBI activation of innate immune cells improved antitumor
response by increasing T cell persistence. Since IL-17 producing CD4+ T cells
(Th17 cells) have a stem memory phenotype (85), we further hypothesized that
polarizing CD8+ T cells to an IL-17 producing phenotype (Tc17) would endow the
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T cell with memory features that would synergize with lymphodepletion. Indeed,
we reported direct correlation with the strength of preconditioning TBI and the
antitumor efficacy of both non-polarized CD8+ T cells (Tc0 cells) and Tc17 cells.
Additionally, the potentiating effects of lymphodepletion were stronger on Tc17
antitumor responses than Tc0.
We found that TBI increased IL-12 and IL-23 secretion by activated dendritic
cells, and that neutralizing IL-12 in irradiated mice greatly hampered the antitumor
response by infused Tc17 cells. Enhancement of Tc17 antitumor immunity by IL12 signaling appeared to be due to a change in function from IL-17 production to
IFN production and higher infiltration of Tc17 cells into the tumor to similar levels
as in fully myeloablated mice. Additionally, TBI increased the memory capacity of
donor Tc17 cells to secrete cytokines upon antigen reintroduction at memory
timepoints. Interestingly, this was not due to a change in memory phenotype as IL12 only increased CD62L on the surface of Tc0 cells, not on Tc17 cells which
expressed nominal levels of CD62L.
Additionally, IL-12 priming ex vivo lowered the requirement for TBI. When
coupled with systemic administration of IL-12 after T cell transfer, IL-12 priming of
Tc17 cells caused durable remission of tumors without preconditioning. These
results underline the importance of both preconditioning and resultant IL-12
signaling in enhancing the capacity and durability of CD8 + T cell antitumor
responses. It also hinted that using a T cell with inherent memory properties such
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as type 17 T cells could ensure optimal synergy between the T cell and the
preconditioned environment.

Successful adoptive cell therapy depends on high numbers of potent tumor
reactive T cells
A key parameter to preparation of T cells for adoptive cell therapy is
expansion to large numbers. Current clinical trials require expansion of tumorreactive T cells to upwards of 6x1010 T cells to ensure the patient receives an
effective dose (42, 49, 86). While necessary, these cell numbers come at a heavy
cost, as CD8+ T cells lose their antitumor potency when they differentiate during in
vitro expansion (46). Similarly, human TILs that undergo shorter expansion and
thus are less differentiated in vitro persist longer in the host, which is linked with
greater tumor regression (53-55, 87).

Th17 cells are potent stem-memory effector cells
To answer the dilemma of generating high yields of less differentiated
tumor-reactive T cells, we sought after a T cell subset capable of rapid proliferation
without loss of memory capacity. Th17 cells are increasingly implicated in a wide
array of autoimmune diseases and are characterized as highly inflammatory longlived effectors (88). As a proposed mechanism of their longevity, Th17 cells have
active Wnt/-catenin signaling (85), which is normally only found in epithelial and
hematopoietic stem cells, but also recently found in Tscm cells (60). Active stem17

signaling in Th17 cells may be due to the cytokine milieu which programs the Th17
cell phenotype namely: TGF, IL-6, IL-21, and IL-1. Of these, IL-6, IL-21 and IL1 are closely tied to stem cell signaling in both cancers and hematopoietic stem
cells. For example, STAT3 downstream of IL-6 is implicated in active stem cell
signaling in pluripotent stem cells (89) and is an important inhibitor of apoptosis in
T cells (90). IL-6 also potentiates IL-21 signaling (91), which itself enhances an
inflammatory phenotype in Th17 cells (78). IL-21 has also been shown to improve
the memory and resultant antitumor efficacy of tumor-reactive T cells expanded in
vitro (76). IL-1 also plays a role in both Th17 polarization and Wnt signaling in
certain cancers (92). Consequently, Th17 cells are the recipients of multiple
stemness signals amenable to instilling durable memory.
Since current efforts to minimize terminal differentiation of CD8+ T cells with
shorter in vitro expansion have had limited success (87), we propose the
employment of Th17 cells which are known to mediate long-lived antitumor
responses (93-95). Additionally, even though Th17 cells are thought to only play
the traditional role of a CD4+ helper T cell, studies show that beyond their ability
to potentiate CD8+ T cell responses (96-98), CD4+ T cells are capable of directly
lysing targets on their own (99, 100). In either case, Th17 cells appear to combine
potent effector function (93) with the molecular signature of Tscm cells (60, 85).
This makes Th17 cells particularly attractive in the context of ex vivo expansion
with the hypothesis that if Th17 cells were truly stem cell-like in nature, they should
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retain their antitumor capacity even after long term ex vivo expansion to large
numbers.

Th17 cells mediate durable memory immunity after long-term ex vivo
expansion
In chapter 2, we tested the durability of Th17 cells to produce antitumor
responses by expanding Th17 cells in vitro for one to three weeks. We discovered
that these differentially expanded Th17 cells had comparable antitumor capacity
on a per cell basis, exerting equal control of established melanomas in mice.
Further investigation showed that while Th17 cells underwent plastic conversion
from IL-17 production to IFN during culture, they exhibited a stable memory
phenotype of Tscm cells with preserved expression of nuclear Tcf7. This correlated
with equivalent capacity to persist in the host no matter the length of expansion.
Comparison to Th1 cells which did not retain antitumor capacity during expansion
showed that Th17 cells were resistant to both apoptosis and senescence during
expansion. The importance of preserved potency over expansion was further
revealed when we could only eradicate large, intractable tumors using the full yield
of Th17 cells expanded for two or three weeks, while the yield of Th17 cells after
one week was not sufficient. Treatment with high numbers of potent Th17 cells
also resulted in long-lasting immunity. Mice receiving these Th17 cells were
protected from multiple tumor re-challenges including psuedometastases in the
lung, further underscoring the durable memory of these cells. In an important step
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towards clinical translation, we also demonstrated that CAR-T cells obtained from
peripheral blood had an undiminished capacity to clear tumors at the end of two
weeks of expansion if polarized to be Th17 cells but not as Th1 cells.

Pharmaceutical induction/preservation of memory in T cells
Another promising method for enhancing the memory of tumor-reactive T
cells is through pharmaceutical manipulation. This has multiple benefits including
simplicity of preparation when compared to bead or fluorescence (FACS) based
sorting of memory T cells. Also, using the drugs solely ex vivo prevents potential
drug-related toxicities to the patient. A frontrunner in this field was the treatment of
T cells with TWS119 which blocks the degredation of -catenin, allowing it to enter
the nucleus and signal. This treatment endowed the cells with the same phenotype
as Tscm cells which were shown to be highly therapeutic (60, 64). A major benefit
from this drug priming strategy was increasing the yield of Tscm cells far beyond
what could be collected through sorting these cells from peripheral blood.
Many studies indicate that effector and memory T cells depend on different
metabolic pathways. Early work noticed that activated T cells abruptly increased
aerobic glycolysis to meet the energy and metabolite demands of proliferation and
function (101, 102), thus a recent study showed that blocking glucose uptake by T
cells with a small molecule inhibitor resulted in less differentiated cells (103). In
contrast, memory T cells depend more on mTOR dependent oxidative pathways
and mitochondrial respiration (104, 105). As a proof of principle, treatment with
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Rapamycin preferentially expanded memory CD8+ T cells with augmented
oxidative phosphorylation (106). Similarly, a recent article found that just
pharmaceutical induction of mitochondrial networking was sufficient to endow the
T cells with the antitumor efficacy of memory T cells (107). Interestingly, these
treatment protocols use reversible inhibitors and yet the effects of these drugs on
the cells are stable. This suggests the tantalizing possibility that transient drug
exposure may lead to fundamental genetic, or epigenetic changes that lock in a
memory phenotype.

T cell memory is enhanced by inhibiting the PI3KAKT signaling pathway
The PI3K/AKT axis plays a central role in shaping a T cell’s phenotype. T
cells express all three class 1A catalytic subunits of PI3K (p110and ), but
p110 is almost exclusively used downstream of the TCR and costimulatory
molecules (108, 109). Thus P110mediates the classical activation of T cells with
resultant proliferation, cytokine production, and cytotoxic function (110).
Additionally, PI3K signaling provides protection of maturing T cells from apoptosis
within the thymus (111) and prevents apoptosis post antigen recognition (112).
This pathway is also important for developing CD8 + T cell memory (113).
Individuals who either have a mutated p110 subunit that is constitutively active,
or a loss of function mutation in the p85 inhibitory subunit, suffer from persistent
upper respiratory tract infection, inflammation, lymphoid organ hyperplasia
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(including splenomegaly), lymphomas and autoimmunity (114). In these patients,
CD8+ T cells rapidly divide and terminally differentiate expressing markers of
exhaustion, which may explain their susceptibility to viral infection (115).
Interestingly, while loss of the P110 subunit results in impaired proliferation and
cytokine production by mouse T cells in Listeria infection (116), it results in
improved clearance of infection with little impact the generation of antigen specific
memory cells (117, 118). However, the improved primary response against acute
infection appeared to be due to impairment of Treg function, and in a subsequent
study the reduced numbers of memory T cells following a primary infection leads
to impaired memory responses (119). In all these reports, it appears that chronic
loss of PI3K signaling results in poor immunity by a reduced number of impaired
CD8+ T cells. In contrast, two studies found that blocking AKT with the reversible
inhibitor AKT VIII (or AKTi) enhanced the memory and antitumor capacity of T cells
in the setting of allograft stem cell transplant for multiple myeloma (120) and
melanoma TIL based ACT (121). Thus, it appears that genetic knockout of
PI3K/AKT signaling does not affect the immune capacity of T cells in the same way
that reversible drug inhibition does.
While PI3K is almost always studied in the context of activating AKT, it has
multiple other downstream targets as well. PI3K is one of the first enzymes
activated by not only the TCR, but other tyrosine receptor kinases, and GPCRs as
well. It’s implicated in cross-regulation with multiple kinase families including the
PKC and MAPK pathways (122-124). Additionally, it’s downstream kinase PDK-1
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(which is the acting kinase on AKT) is considered the “master kinase” of the AGC
family as it phosphorylates protein kinase A, G, and C families as well as a variety
of lesser known kinases (125). Thus, we expected that blockade of PI3K would
not only induce a T cell memory phenotype similar to what AKT inhibition
generates, but would do so more potently. We therefore tested whether inhibiting
the p110 subunit of PI3K compared to direct AKT inhibition would induce an even
stronger memory phenotype and endow a more potent antitumor capacity in T
cells.

Idelalisib (CAL-101): a potent drug with great potential in ACT
Our understanding of the PI3K/AKT axis is due largely to studies in human
cancers where it is also canonically associated with proliferation and resultant
regulation of metabolism, cell cycle, and apoptosis (126). As a major target of drug
discovery research, this pathway now has multiple potent and specific inhibitors
(127). Among these is Idelalisib (CAL-101) which was developed to specifically
block P110 signaling in hematologic malignancies. After studies showed the drug
was highly effective in treating acute myelocytic leukemia (128), acute
promyelocytic leukemia (129), and refractory CLL and non-hodgkin lymphoma
(130), the FDA approved Idelalesib for use in a variety of blood cancers.
However, at the same time, evidence was mounting that along with clearing
B cell malignancies, this drug also depleted Tregs causing serious and fatal cases
of hepatotoxicity, sepsis, gastroenteritis and pneumonitis. This led to a black box
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warning and relegation of Idelalisib to 3rd or 4th line treatment. Yet, among all these
studies of its effects on both the cancer and peripheral tolerance, its impact on
effector T cells remains poorly understood. Thus, if the memory induced by AKTi
inhibition could be translated to PI3K blockade, then an already FDA approved
and powerful drug remained available for enhancing tumor-reactive T cells in the
safety of ex vivo T cell preparation.

Imprinting memory in tumor-reactive T cells via blockade of P110
In chapter 3, we compared blockade of P110 and AKT in both murine
effector CD8+ T cells from pmel-1 mice and human peripheral CD3+ T cells. In
pmel-1 cells, AKT blockade increased the frequency of CD62L expressing cells
and a predominant CD44hiCD62Lhi phenotype as expected. However, P110
blockade increased CD62L on the cells to a higher extent than AKT blockade, and
lowered CD44 expression lending a phenotype to the cells normally associated
with naïve T cells. P110 blockade also induced the highest expression of CD127,
indicating higher responsiveness to IL-7. CAL-101 treated T cells persisted at the
highest levels compared to AKT blocked and untreated T cells one week after
infusion. Thus, while AKT blockade marginally improved tumor control over vehicle
treated mice, blocking P110 signaling greatly enhanced tumor control.
We saw similar phenotypic changes in human CD3 + T cells with increased
levels of CCR7 and CD127 after P110 blockade. Interestingly, we also noticed
higher levels of the transcription factor Tcf7 in the nuclei of T cells receiving P110
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blockade versus AKT blockade and vehicle. When transduced with a CAR specific
for mesothelin tumor antigen, CAL-101 primed T cells controlled tumors longer
than vehicle and AKTi treated CAR-T cells.
It remained unclear whether increased CD62L, CCR7, and CD127 from
P110 blockade were driving the improved antitumor response, or merely markers
of a more potent T cell. We therefore tested the importance of the memory markers
CD62L and CD127 in the memory response of these T cells against tumor. We
found that while CD62L+ T cells from vehicle treated T cells looked phenotypically
like CAL-101 primed T cells, they could not match the antitumor potency of CAL101 primed cells and were no more effective than unsorted bulk T cells. Despite
neutralization of IL-7 for two weeks after T cell transfer, CAL-101 primed cells
engrafted and controlled tumor similar to CAL-101 primed T cells in isotype control
mice. Thus, while our understanding of T cell memory started with recognizing
memory T cells by expression of CD62L, CCR7, and CD127, we are finding that
these molecules do not fully explain why memory T cells deliver stronger antitumor
responses. We posit that other pathways such as proteins transcribed by the catenin pathway may be more crucial drivers of T cell durability and potency.
Through the last three decades, ACT has grown from a little-known therapy
conducted at one research center, to a worldwide effort to direct T cells against a
variety of malignancies. As our understanding of basic principles of T cell immune
responses increases, our ability to manipulate the T cells to exert stronger
antitumor responses also improves. This dissertation compiles findings which
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endorse multiple methods for preparing a more effective cellular product for ACT
including the use of preconditioning, selecting stem memory effector cells such as
Th17 cells, and pharmaceutical enhancement of tumor-reactive T cells via P110
blockade.

26

Chapter 2: Materials and Methods

Mice and Tumor lines
Mice. C57BL/6J (B6), CD45.1 congenic B6, TRP-1 and pmel-1/Thy1.1 TCR
transgenic mice and NOD/scid/gamma chain knock out (NSG) mice were
purchased from Jackson Laboratories and housed and bred in the Medical
University of South Carolina Hollings Cancer Center (MUSC, Charleston, SC)
comparative medicine department. NSG mice were housed under specific
pathogen-free conditions in microisolator cages and given autoclaved food and
acidified water. Housing and experiments were conducted in accordance with
MUSC’s Institutional Animal Care and Use Committee’s (IACUC) procedures.
Tumor Lines. B16F10 (H-2b) melanoma tumor, gift of the Nicholas Restifo
lab at NCI surgery branch was maintained in culture media (RPMI 1640 w/ Lglutamine, 10% FBS, 1% Pen/strep, NEAA, and Na Pyruvate, and 0.1% BME and
Hepes). M108 xenograft tumors were a gift from the June lab at the University of
Pennsylvania. M108 were cultured and engrafted as described previously (38).

Cell preparation and culture
Pmel-1 CD8+ T cells. Splenocytes were harvested from Vβ13+ Pmel1/Thy1.1 TCR transgenic mice. Cells were cultured in complete medium and
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stimulated with 1μM human gp10025-33 peptide (KVPRNQDWL) in 48 well plates
(1 mL media containing 1 × 106 cells/well). CD8+ T cells polarized at activation
towards Tc0 (100 IU/mL rhIL-2) or Tc17 (100 ng/mL rhIL-6, 30 ng/mL rhTGF-, 10
μg/mL anti-mouse IL-4, 10 μg/mL, anti-mouse IFN-). If T cells were primed,
priming occurred on day 1 or 2 by adding rmIL-12 (40 ng/mL) or rmIL-23 (60 ng/mL)
where indicated. Cells were split every day starting from day 3 and Tc17 cells
supplemented with 20 IU/mL rhIL-2 while Tc0 cells continue to be expanded with
100 IU/mL rhIL-2. For drug priming experiments, starting 3 hours after initial
activation, cells were treated with either DMSO vehicle, AKT inhibitor VIII (AKTi)
at 1M (Calbiochem), or CAL-101 at 10M (Selleckchem). Cells were
supplemented with culture media containing 100 IU rhIL-2/mL and vehicle or drug
when expanded. Where indicated, CD8+ T cell cultures were in vitro activated with
feeder cells and peptide 12 hours before transfer as described (131).
TRP-1 CD4+ T cells: TRP-1 splenocytes were activated using 10 Gy
irradiated B6 splenocytes (feeder cells) pulsed with 1M TRP-1 peptide and
polarized to a Th17 phenotype at 3e6 cells/2 mL of cell media in one well of a 24
well plate with the following cocktail: 100 ng/mL rhIL-6 (NIH repository), 100 ng/mL
rhIL-21 (Shenandoah), 30 ng/mL rhTGF1 (Biolegend), 10 ng/mL rhIL-1 (NIH
Repository), 10g/mL each of anti-mIFNclone XMG1.2, anti-mIL-4 clone 11B11,
and anti-mIL-2 clone JES6-1A12 (BioXcell). Th1 polarization occurred under
peptide activation with irradiated feeder cells with the following cocktail: 3 ng/mL
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rmIL-12 (Shenandoah), 100 IU/mL rhIL-2 (NIH repository), and 10g/mL anti-mIL4 clone 11B11 (BioXcell). Cultured cells were supplemented with new media
containing 100 IU/mL rhIL-2 (NIH repository) throughout expansion, then
cryopreserved at time-points indicated in 10% DMSO in FBS. One day before
transfer, cells were thawed and plated in cell media overnight and then transferred
into mice.
Human Normal Donor Peripheral T cells: To generate mesothelin-specific
CAR-Th17 cells, human CD4+ T cells were activated with CD3/CD28/ICOS coated
beads and programmed to a Th17 or Th1 phenotype and then transduced with a
chimeric antigen receptor (CAR) that contained either an anti-mesothelin, or antiCD19 single-chain variable fragment (scFv) fusion protein containing the T cell
receptor  (TCR) signaling domain and 4-1BB that was generated as described
previously (38) (gifts from the June lab) . CD4+ T cells were polarized to Th17
phenotype as follows: 10 ng/mL rhIL-1, 10 ng/mL rhIL-6, 20 ng/mL rhIL-23, 10
g/mL anti-hIL-4 clone 11B11, and anti-hIFN clone H22 (eBioscience).
Experiments were conducted with fetal calf serum containing endogenous sources
of TGF-. Th1 cells were polarized as follows: 10 g/mL rhIL-12 and 100 IU/mL
rhIL-2. Cell cultures were maintained with 100IU/mL of rhIL-2 and cells were
expanded for up to two weeks. Likewise, human CD8 + T cells were activated with
CD3/CD28/ICOS beads and redirected with either the anti-meso or anti-CD19
CAR constructs. For pharmaceutical assays, polyclonal CD3+ T cells were
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prepared via negative bead selection (Dynal) from peripheral blood lymphocytes
and activated using CD3/CD28 beads (Gibco) with 100 IU rhIL-2/mL and either
DMSO vehicle or drug. On day 2 of culture, T cells were engineered the antimesothelin CAR. IL-2 and vehicle or drug were administered in fresh CM as T cells
were expanded throughout culture.

Adoptive cell therapy
B6 mice were given 4.5e5 B16F10 cells subcutaneously between 5-12 days
before ACT. One day before therapy, mice received nonmyeloablative 5 Gy total
body irradiation (non-myeloablative) or 9 Gy (myeloablative) TBI. HSCs, given to
mice treated with 9 Gy TBI, were extracted from the bone marrow by lineage
depletion

with

streptavidin-coated

magnetic

beads

(Dynabeads

M-280

Streptavidin; Dynal Biotech) against biotin-labeled antibodies ( T cell receptor,
 T cell receptor, CD4, CD8a, NK1.1, Gr-1, B220, Ter-119, CD2, CD11b; BD
Biosciences) followed by a c-kit enrichment with CD117 Microbeads (Miltenyi
Biotec) and cultured for 18 hours in 10% DMEM with 50ng rmIL-3, 500ng rmIL-6,
and 500ng rmCSF (PeproTech); 1 × 105 cells were administered one day postirradiation. The mice were treated via adoptive transfer of T cells infused via tail
vein. In the experiments with pmel-1 CD8+ T cells, T cells were in vitro activated
when indicated, then starting on the day of ACT, mice were given intraperitoneal
injections of 600,000 IU rhIL-2 every other day for a total of 6 doses. IL-2 complex
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was prepared at 1.5g rhIL-2 (NIH) and 7.5g anti-IL-2 antibody (clone JES6-1A12
BioXCell) per mouse and administered via intraperitoneal injections on days 0, 2,
and 4 of treatment. Serial tumor measurements were obtained and tumor area was
calculated by multiplying the perpendicular diameters, then plotted.
NSG mice were given 5-6e6 M108 suspended in matrigel subcutaneously
as previously described (38). Tumors established for 40-50 days prior to adoptive
therapy. In all experiments, mice were randomized to treatment groups and tumor
burden

was monitored

in

blinded fashion

using

perpendicular

caliper

measurements and reported as tumor area (mm2).

In vivo cytokine neutralization
IL-12 family cytokine neutralization. Neutralizing antibodies against murine
IL-12p35 (MMp35A1.6; eBioscience) or IL-23p19 (AF1619; R&D systems) were
administered beginning at 0 hours post-transfer, via intraperitoneal injection with
100μg neutralizing antibodies and repeated every other day for 5 cycles. The
control group received isotype-matched antibody.
CD8+ T cell depletion. mice received weekly intraperitoneal injections with
100g either anti-CD8 depleting antibody clone 53-6.72 or Isotype control clone
2A3 (BioXcell) beginning the day before adoptive cell transfer and continuing
weekly throughout the duration of the experiment.
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IL-7 cytokine neutralization. Mice received 200g of either IL-7 neutralizing
antibody (clone M25) or IgG2b isotype (clone MPC-11) (BioXCell) on days 0, 3, 5,
8, 12, and 17 of treatment via intraperitoneal injection as previously described (73).

Vitiligo Autoimmunity Score.
Severity of autoimmune vitiligo was scored after the phenotype stabilized.
Depigmentation was rated based on a graduated scale from 1 to 5 with 1 being no
loss of pigment (all black) and 5 being total loss of pigment (all white). Mice were
scored in blinded fashion in triplicate.

Tissue Distribution Analysis
Spleens from treated mice were harvested and mechanically disrupted
using the tip of a syringe plunger. Cells were filtered through a wire mesh, red
blood cells lysed with RBC lysis buffer (Biolegend), and then re-suspended in cell
media for analysis. Eyes and tumors were sectioned, then incubated in 1 mg/mL
collagenase type II (life technologies) at 37°C for one hour. Disgested tissue was
filtered, re-suspended in cell media and plated for assay. Before probing with
antibodies, FC block (Biolegend) was applied to cells at 1 g/100 L. Cell
suspensions were then analyzed by flow cytometry.
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Flow Cytometry, in situ flow cytometry, and ELISA
Flow Cytometry. Surface stains were performed in 2% FBS in PBS.
Intracellular staining of cytokines and transcription factor stains occurred after
surface staining, intracellular staining with antibodies was performed according to
the manufacturer’s protocol using Fix and Perm buffers (Biolegend). For
intracellular stains, cultured cells were restimulated with either 1μM human
gp10025-33 peptide for pmel-1 cells or TRP-1 peptide for TRP-1 cells using
irradiated splenocytes as antigen presenting cells (1:5 T celll:Irradiated
splenocytes) from C57BL/6 mice for 5 hours or generically restimulated with PMA
and Ionomycin. Monensin (Biolegend) was added after one hour of stimulation with
the peptide. Data were acquired on FACSVerse or Accuri (BD Biosciences). All
data were analyzed with FlowJo software (Tree Star).
Antibodies used: anti-mCD3-efluor450 clone 17A2, anti-h/mRort-PE
clone AFKJS-9 (eBioscience), anti-m4-1BB-Biotin clone 17B5, anti-m4-1BBL-PE
clone TKS-1, anti-hCCR6-PECy7 clone G034E3, anti-hCCR10-PE clone 6588-5,
anti-hCD4-APCCy7 OKT4, anti-mCD8-PerCPCy5.5 clone 53-6.7, anti-mCD8PECy7 clone YTS156.7.7, anti-hCD8-PerCPCy5.5 clone SK1, anti-mCD25-FITC
clone 7D4, anti-hCD25-APCCy7 clone BC96, anti-mCD27-PECy7 clone LG.3A10,
anti-mCD28-PerCPCy5.5 clone 37.51, anti-h/mCD44-PerCPCy5.5 clone IM7, antihCD45RO-APC clone UCHL1, anti-hCD62L-FITC clone DREG-56, anti-mCD69PECy7 clone HI.2F3, anti-mCD70-APC clone FR70, anti-mCD127-PE/V450
A7R34, anti-hCD127-PECy7 clone A019D5, anti-hCXCR3-AF647 clone G025H7,
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anti-mF4/80-PECy7 clone BM8, anti-mH-2Db-PE clone 28-14-8, anti-mICOSL-PE
clone HK5.3, anti-mIFN--BV421 clone XMG1.2, anti-mIL-10-FITC clone JESF16E3, anti-mIL-17A-PE clone TCII-18H10.1, anti-mLAG3-PE clone C9B7W, antimLy6C-APCCy7 HK1.4, anti-mLy6G-FITC clone 1A8, anti-mOX40L-PerCPCy5.5
clone RM134L, anti-mPD1-PerCPCy5.5 clone 29F.1A12, Streptavidin-BV 421,
anti-mTIM3-PE clone B8.2C12, anti-hTIM3-PE clone F38-2E2, anti-mTNF-PECy7 clone MP6-XT22, and, anti-mV13-PE/APC clone MR12-3/MR12-4
(Biolegend), anti-hCCR5-V450 clone 2D7/CCR5, anti-mCCR7-PE clone 4B12,
anti-hCCR7-PECy7 clone CCR7, anti-hCD4-APCH7 clone RPA-T4, anti-mCD4APC/PE/APCCy7 clone RM4-5, anti-hCD8-V450 clone RPA-T8, anti-mCD11b-PE
clone M1/70, anti-mCD11c-APC clone HL3, anti-mCD45.1-APCCy7 clone A20,
anti-mCD45.2-V500 clone 104, anti-mCD62L-APC clone MEL-14, anti-mCD80FITC clone 16-10A1, anti-mCD86-PE clone GL1, anti-mCD95-PECy7 clone Jo2,
anti-mICOS-Biotin clone 7E.17G9, anti-mKLRG1-APC/V450 clone 2F1, antimNK1.1-PE clone PK136, anti-hPD1-FITC clone M1H4, anti-h/mTbet-AF647
clone 4B10, anti-mV14-FITC clone 14-2 (BD). Cell viability assessed via Zombie
Live/Dead Stain (biolegend).
In situ flow cytometry. Apoptosis assays were performed with Biolegend’s
FITC Annexin V Apoptosis Detection Kit with PI, per manufacturer’s instructions.
Telomere length was measured using the Telomere PNA Kit/FITC via Flow (Dako)
per manufacturer’s instructions.
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ELISA. ELISAs for IL-17A, IL-17F, IL-22, IFN, and IL-2 were performed
using DuoSet ELISA kits (R&D) per manufacturer’s instructions and read on a
thermoscan spectrophotometer (Thermofisher).

In vivo Cytotoxic Assay
C57BL/6 splenocytes were incubated with either TRP peptide or OTII
peptide then labeled with a low level (0.5M) or high level (5M) of cell trace violet
(CTV) (Thermo Fisher Scientific) respectively. TRP and OTII-pulsed splenocytes
were mixed at equal ratio then injected intravenously into mice previously treated
with Th17 cells or untreated control mice. After 12 hours, spleens were harvested
from mice and the ability of donor cells to lyse TRP-pulsed splenocytes vs. OTIIpulsed splenocytes was assessed via flow and reported as % specific lysis using
the following equation: % specific lysis = (1- (ratio of no T cell control mice) / (ratio
of ACT mice)) x 100, where ratio = % OTII / % TRP).

Western blot
Nuclear protein from Th17 cells cultured for 7, 14, or 21 days was extracted
via NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific) then
subjected to western blot. The following primary antibodies were used: mouse antih/m -catenin clone 14/beta-catenin (BD), rabbit anti-h/mHistone H3 clone D1H2,
rabbit anti-h/m Lef1 clone EP2030Y (abcam), rabbit anti-h/mSTAT1 polyclonal,
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rabbit anti-h/mSTAT3 clone D3Z2G (Cell Signal), rat anti-h/mRORt clone AFKJS9, rabbit anti-h/mTCF7 clone EPR2035 (abcam), mouse anti-h/mTbet clone 4B10
(eBioscience). Quantification of blots was performed using Fiji analysis software
(NIH).

Histology
For lung histology and morphometry, lungs were inflated en-bloc and fixed
with 4% buffered paraformaldehyde at a constant hydrostatic pressure of 25 cm
and further immersed in fixative for 48 hours. The inflated lungs were embedded
in paraffin and 4 μm sagittal stepped sections were stained with hematoxylin and
eosin (H&E) for histological evaluation. In total 10 stepped sections from each lung
were analyzed to calculate the volume of metastatic tumor in each group using an
automated motorized stage Olympus BX61 scope to generate lung superimages
using Visiopharm software. The total area of lung and tumor mets was calculated
using Visiopharm image acquisition software by an observer blinded to the
experimental groups.

RNA sequencing
Library preparation: mRNA libraries were prepared using the TruSeq
RNA V2 kit(Illumina). Cleaved RNA fragments were copied into first strand cDNA
then underwent second strand cDNA synthesis. End repair of cDNA fragments,
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single ‘A’ base addition and ligation to the adapter followed. The product was then
purified and enriched with PCR to create the final cDNA library. Transcriptome
sequencing: cDNA libraries were clonally clustered onto the sequencing flow cell
using the c-BOT (Illumina) Cluster Generation Station and Hiseq Rapid PairedEnd Cluster Kit v2 (Illumina). Clustered flow cells were sequenced on the
Illumina HiSeq2500 Sequencing System using the Hiseq Rapid SBS Kit V2
(Illumina).

Statistics
Kaplan-Meier survival curves were assessed for significance using a log
rank test between treatment groups. A p-value of <0.05 was considered significant.
Comparisons between two groups were analyzed using a two-tailed student’s ttests with Welch’s correction for parametric distribution or Mann-Whitney signed
rank tests for non-parametric distribution. A p-value of <0.05 was considered
significant. For comparisons between multiple groups, a one-way repeated
measures ANOVA was performed. A p-value of <0.05 was considered significant.

Study Approval
Studies were approved by the IACUC of the Medical University of South
Carolina (ARC #3039). De-identified human PBMCs were collected under
approval of our IRB (pro13570). Human T cells were engineered via approval from
the IBC (2335).
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Chapter 3: Enhanced function and prolonged antitumor activity of
adoptively transferred Tc17 cells via IL-12 signaling

Introduction
The tumor is a notoriously immunosuppressive environment where tumorreactive T cells are thwarted by a variety of inhibitory signals (9-11).
Lymphodepletion with total body irradiation (TBI) prior to transfer of tumorinfiltrating or gene-engineered T cells improves treatment outcome in cancer
patients (132) in part by depleting immunosuppressive host cells. These
immunosuppressive cells include myeloid-derived suppressor cells (MDSCs),
regulatory T cells (Tregs) and other cells that compete for homeostatic -chain
cytokines such as natural killer cells and non-tumor-specific T cells (96, 133, 134).
Lymphodepletion also enhances the antitumor activity of CD8 + T cells by activating
innate immune cells via microbial translocation, a process that promotes the
liberation of gut microbes from the compromised bowel into the blood (84). Recent
findings revealed that activated dendritic cells (DCs) from lymphodepleted patients
secrete pro-inflammatory cytokines IL-12 and IL-23, which further improve the
function of human tumor-infiltrating CD8+ T cells (135). Preclinical work has
demonstrated that lymphodepletion resets DC homeostasis and increases their
capacity to secrete IL-12, while reducing their ability to produce IL-10, resulting in
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better T cell priming and antitumor responses (136). While the role of
lymphodepletion on IL-2-expanded CD8+ T cells (Tc0 − i.e. classic IFN-+CTLs) is
well studied, how and to what extent lymphodepletion regulates the plasticity,
memory, and antitumor activity of IL-17A-producing CD8+ T cells (Tc17) remains
unclear. Given that murine and human IL-17A-producing T cells have shown
preclinical promise in adoptive cell transfer (ACT) therapies (93, 94, 137), it is
important to understand how lymphodepletion regulates antitumor Tc17 cells.
An important benefit of lymphodepletion is the promotion of homeostatic
cytokine production by the host (81) which in combination with the removal of
cytokine sinks, creates an environment where T cells can engraft at high numbers
and persist (74, 138). In a recent study, IL-12 (which is also produced after TBI),
primed CD8+ T cells to be more responsive to homeostatic cytokines, including IL7 (73). This is important as IL-7 is classically known to support naïve and memory
cells (72). Thus, IL-12 seems to support CD8+ T cell memory. IL-17 producing T
cells are reported to have active Wnt/-catenin signaling, a characteristic of stem
memory T cells (Tscm) which exert long-lived protection against tumors (60, 64).
We hypothesize that IL-17 producing CD8+ T cells (Tc17) would therefore
synergize with lymphodepletion due to a durable memory phenotype. Thus, we
propose that Tc17 cells will be able to exert stronger and more durable antitumor
responses because of their inherent memory properties and improved
responsiveness to TBI induced cytokine signals.
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In addition to its effects on memory, we hypothesized TBI would also impact
Tc17 function through a process called plasticity. Certain CD4+ T helper (Th)
subsets display considerable functional plasticity; that is, Th17 cells can be
converted to Th1 cells or Treg cells, under distinct polarizing conditions (139).
Likewise, Th2 cells can convert into a unique IL-9-secreting subset called Th9 cells
(140). In contrast, Th1 cells are considered functionally less plastic. As Tc17 cells
represent a recently described IL-17-producing CD8+ T cell population, the
capacity and extent of plasticity of this subset and its consequence in tumor
immunity has yet to be fully appreciated. Several labs have shown that plasticity in
CD8+ Tc17 cells exists in vivo, as IL-17A-secretors convert to IFN--secreting T
cells in mice and promote destruction against tumors in lymphodepleted mice (137,
141-143). Additionally, Th17 cells can convert to Th1 cells and induce diabetes to
a greater extent in lymphopenic hosts than in non-lymphopenic animals (144).
Together, these studies suggest that host preconditioning regulates the
pathogenicity of Tc17 cells. Herein, we investigate how lymphodepletion regulates
the functional plasticity and antitumor capacity of Tc17 cells in mice with
established melanoma.
We show that increasing the intensity of lymphodepletion from a nonmyeloablative (5 Gy) to a myeloablative (9 Gy) TBI preparative regimen (which
requires hematopoietic stem cell (HSC) support) accentuates the antitumor
capacity of both Tc0 and Tc17 adoptively transferred T cells, in part by increasing
their infiltration into the tumor. In the case of Tc17 cells, increasing the level of TBI
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accelerated the conversion of Tc17 IL-17A producers into IL-17A/IFN- double
producers and IFN- single producers. Tc17 cells mediated superior tumor
regression in myeloablated mice compared to lymphoreplete or non-myeloablated
mice. Additional investigations revealed that TBI altered the composition of the
host’s myeloid compartment including enhancing the number of host DCs,
macrophages and granulocytic MDSC before their eventual disappearance. DCs
were strongly activated via TBI, as indicated by their elevated expression of
several co-stimulatory molecules post-irradiation. Escalating the level of irradiation
also increased IL-12 and IL-23 secretion by irradiated DCs to a greater level than
macrophages. As cytokines in the IL-12 family differentially regulate the function
of Tc17 cells in vitro, we sought to determine how these TBI-induced cytokines (IL12 versus IL-23) impact the memory, function and antitumor activity of Tc17 cells
in vivo. Blockade of IL-12 (but not IL-23) reduced the antitumor activity of Tc17
cells in myeloablated mice. Conversely, Tc17 cells primed with IL-12 in vitro
enhanced tumor regression in vivo and IL-12 priming increased Tc17 frequencies
compared to host lymphocytes and enhanced their infiltration into the tumor similar
to myeloablation. In vitro, Tc17 cells co-expressed RORt and T-bet and cosecreted IFN- and IL-17A when primed with IL-12. Of clinical significance,
administration of IL-12 to lymphoreplete (non-irradiated) mice further enhanced the
antitumor activity of Tc17 cells (in vitro primed with IL-12), leading to long-term
cures in mice without the need for lymphodepletion. These studies suggest that
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TBI-induced IL-12 enhances Tc17 memory, plasticity and induces durable
antitumor activity, a finding that may have a role in the cellular therapy of cancer.

Lymphodepletion augments the antitumor capacity of Tc17 cells more than
Tc0 cells
A non-myeloablative preparative regimen consisting of 5 Gy total body irradiation
(TBI) prior to adoptive cell transfer (ACT) of IFN-+CD8+ T cells (Tc0), vaccination
with vaccinia virus hgp10025-33 and bolus IL-2 induces regression of established
B16F10 melanoma in mice (133). Increasing lymphodepletion to a myeloablative
regimen requiring 9 Gy TBI and stem cell support augments ACT therapy without
the need for vaccination (145). (Vaccine independence may be a key feature in the
translation of these findings to humans, as vaccines for transferred T cells are not
always available.) The mechanisms by which patient preconditioning with TBI
enhances ACT treatment outcome is multifaceted, consisting of depleting 1) host
lymphocytes that act as cytokine sinks (homeostatic cytokines are essential for the
engraftment and expansion of infused T cells), 2) suppressive regulatory T cells
and 3) myeloid derived suppressor cells (MDSCs) within the tumor while
concomitantly activating 4) antigen presenting cells (APCs) of the innate immune
system (84, 146). While lymphodepletion augments the engraftment, function and
antitumor activity of infused Tc0 cells, it is unclear how and to what extent different
intensities of host preconditioning impacts the antitumor properties of IL-17Apolarized CD8+ T cells (Tc17), a lymphocyte subset
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that has shown promise in preclinical tumor models (137). We hypothesized that
increasing the level of host preconditioning would augment the antitumor activity
of Tc17 cells to a greater extent than Tc0 cells. To test this idea, we preconditioned mice bearing 7 day old B16F10 melanoma tumor with either nonmyeloablative (5 Gy) or myeloablative (9 Gy plus 10 4 hematopoietic stem cell
transplantation) lymphodepletion regimens one day before transfer of pmel-1 Tc0
or Tc17 cells (pmel-1 cells: TCR Tg reactive against the tumor antigen gp100).
Lymphoreplete mice were used as a control (0 Gy). Mice were not vaccinated with
hgp10025-33-expressing vaccinia virus, but were treated with bolus high dose IL-2.
We found that adoptive transfer of pmel-1 CD8+ T cells programmed to a Tc17
phenotype mediated greater regression of melanoma than pmel-1 Tc0 cells in all
conditioning regimens (Figure 3-01A-C). Moreover, a myeloablative regimen (9 Gy
+ HSC) was superior to non-myeloablative preconditioning (5 Gy) in augmenting
the antitumor activity of transferred pmel-1 Tc17 cells, resulting in curative memory
responses in myeloablated mice (9 Gy + HSC>5 Gy, Figure 3-01B-C).

Higher doses of TBI increase the numbers of both Tc0 and Tc17 cells in the
tumor
Given that pmel-1 Tc17 cells mediate superior antitumor responses in
myeloablated mice than Tc0 cells (Figure 3-01C), we hypothesized that Tc17 cells
traffic to the tumor more efficiently than Tc0 cells. We also posited that donor Tc17
cells prevailed at a higher ratio to remaining inhibitory host cells (i.e.
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Figure 3-01. Adoptively transferred Tc17 cells are uniquely enhanced by a
myeloablative preparative regimen.
5

C57BL/6 mice were injected with 3x10 B16F10 melanoma. After 10 days, these
mice were infused with either ten million Tc17 or Tc0 cells and high dose rhIL-2
after either (A) no irradiation (0 Gy), (B) non-myeloablative 5 Gy TBI, or (C)
myeloablative 9 Gy TBI with hematopoietic stem cells (HSC) one day prior to
transfer. Data are representative of 3 independent experiments (mean ± SEM;
n=5 mice per group). * = p<0.05, ** = p<0.01, *** = p<0.001, one way repeated
measures ANOVA.
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host CD8, CD4 and NK cells) than donor Tc0 cells in myeloablated mice. To test
this concept, we evaluated the impact of a nonmyeloablative (5 Gy) versus
myeloablative (9Gy+HSC) preparative regimen on the engraftment of transferred
pmel-1 Tc0 or Tc17 cells to the remaining host cells in the tumor of mice. We used
the congenic marker V13 to distinguish pre-activated donor Pmel-1 Tc0 or Tc17
cells from the ablated host cells in mice that received TBI. As Wrzesinski et al.
reported (145, 147), we also found that transferred pmel-1 Tc0 prevailed at a
higher ratio to remaining host CD8+T, CD4+T and NK cells in the tumor of mice
receiving myeloablative TBI with HSC transplant (9 Gy + HSC) when compared
with mice receiving no irradiation (0 Gy) or a nonmyeloablative regimen (5 Gy)
(Figure 3-02A-C).
In contrast to our hypothesis, transferred pmel-1 Tc17 cells trafficked to the
tumor at a comparable ratio against host CD8+ T cells as pmel-1 Tc0 cells (Figure
3-02A) in all regimens. Interestingly, only in the myeloablative setting (9 Gy + HSC)
did transferred Tc17 cells reside in the tumor at a slightly higher ratio to host CD4 +
T and NK cells compared to transferred Tc0 cells (Figure 3-02B-C). Since TBI
appeared to enhance donor Tc17 cells infiltration into the tumor over host elements
as effectively as donor Tc0 cells at all three levels of host preconditioning (0, 5 and
9 Gy + HSC), it remained unclear why escalating TBI doses preferentially
enhanced the antitumor activity of pmel-1 Tc17 cells.
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Figure 3-02. Tumor infiltration by Tc0 and Tc17 cells is enhanced in a dose
dependent manner by TBI.

Mice bearing B16F10 melanoma were conditioned with either 0 Gy, 5 Gy, or 9
6
Gy (+HSC) TBI, before infusion of 10 Tc0 or Tc17 cells. Ratio of donor
+
+
(CD8 Vβ13 ) T cells to host (A) CD8+, (B) CD4+ and (C) NK1.1+ NK cells in the
tumor as assayed by flow cytometry 5 days after transfer. Representative of two
independent experiments.
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TBI causes plastic conversion of Tc17 and a higher response to antigen restimulation than Tc0 cells
To determine whether TBI enhanced the function of the transferred Tc17
cells more than Tc0 cells in vivo, we measured IL-17A and IFN- secretion by
infused pmel-1 Tc17 or Tc0 cells before (day -1) and after transfer (day 2 and day
20) into mice given different TBI preconditioning regimens. Prior to transfer, pmel1 Tc0 and Tc17 cells secreted high levels of IFN- and IL-17A, respectively, upon
hgp10025-33 antigen re-stimulation (Figure 3-03A). Further, as previously reported
(145, 147), increasing the level of lymphodepletion augmented the function of
pmel-1 Tc0 cells in vivo, as indicated by their increased capacity to secrete IFN-.
On day 2 post-transfer, IFN- production by pmel-1 Tc0 cells was highest in mice
given 9 Gy TBI (72%), followed by mice given 5 Gy TBI (61%) versus those not
given TBI (54%). Pmel-1 Tc17 cells produced nominal IFN- but ample IL-17A two
days after infusion into non-irradiated mice. Interestingly, the greatest functional
plasticity of pmel-1 Tc17 cells was observed in those infused into mice pretreated
with 9 Gy TBI (+HSC), as these cells dramatically converted from mainly IL-17A
producers (day -1 before transfer) into those that co-secrete ample IL-17A and IFN (25%) and IFN- alone (31%) two days after infusion (Figure 3-03B). By day 20,
transferred pmel-1 Tc17 cells produced no IL-17A but high amounts of IFN-. To
our surprise, by day 20, transferred pmel-1 Tc17 cells produced more IFN- than
pmel-1 Tc0 cells at any level of lymphodepletion indicating an increased memory
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Figure 3-03. TBI induces plastic conversion of Tc17 cells to IFN- production.

IFN- and IL-17 production by pmel-1 Tc17 or Tc0 cells (A) one day before, and
(B) 2 or (C) 20 days after transfer into mice given increasing levels of TBI. Data
representative of 3 independent experiments, n=3 mice per group.
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capacity of the transferred cells to mount a recall response to antigen (Figure 303C). Our data show that increasing the intensity of host preconditioning rapidly
converts Tc17 cells from IL-17A to IFN- producers in myeloablated mice and Tc17
cells ultimately secrete more IFN- than Tc0 cells. Both the magnitude and duration
of this improved Tc17 functionality may account for the pronounced tumor
destruction observed in myeloablated mice compared with non-irradiated or nonmyeloablated mice.

Lymphodepletion enhances the activation and maturation of DCs
Because dendritic cells (DCs) are the APCs specialized for triggering T cell
responses (148), we hypothesized that an increase in the activation of host DCs
following TBI was responsible for initiating the functional plasticity (Figure 3-03)
and antitumor activity of pmel-1 Tc17 cells in myeloablated mice (Figure 3-01C).
To test this idea, we first examined the fate of host DCs and macrophages in the
spleens of B6 mice following host preconditioning with either a non-myeloablative
(5 Gy) or myeloablative (9 Gy + HSC) preparative regimens compared to host DCs
and macrophages in lymphoreplete animals (0 Gy-control). TBI reduced the overall
cellularity of recipient spleens 12 hours after both a non-myeloablative (5 Gy) or
myeloablative regimen (9 Gy + HSC), (90.3% and 93.3% respectively) (Figure 304A). However, the frequency of host CD11c+CD11b+ DCs and CD11b+F4/80hi
macrophages increased substantially in recipient spleens (Figure 3-04B). Further,
the absolute number of host DCs (but not macrophages) declined slightly 12 hours
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following TBI (Figure 3-04C), and by day 5 >95.0% of host DCs and macrophages
in the spleen were eliminated in irradiated animals (not shown). Since T cell
activation is induced by mature DCs in vivo (148), we next sought to determine if
host DCs might be differentially activated following various levels of
lymphodepletion but prior to their disappearance. Twelve hours post TBI, host DCs
from irradiated mice (5 Gy and 9 Gy + HSC) dramatically increased their
expression of MHC I (H2-Db) and costimulatory ligands CD86, CD80, ICOS ligand
(ICOSL), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L) and CD70 (Figure 3-04D).
To our surprise, only OX40L expression was increased in macrophages 12 hours
after TBI (Figure 3-04D). Collectively, our data suggest that TBI induces the
activation of host DCs before their rapid elimination, but if TBI regulates the ability
of pre-terminal DCs to secrete pro-inflammatory cytokines and influence
transferred T cells remains unclear.
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Figure 3-04. TBI enhances the frequency and activation status of host DCs.

(A) total number of splenocytes in mice 12 hours after preconditioning with 0, 5,
+
hi
+
hi
or 9 Gy TBI. (B) Frequency of CD11b CD11c DCs and CD11b F4/80
macrophages in spleens of nonirradiated, 5 Gy and 9 Gy irradiated mice. Data
are representative of three independent experiments (n= 7 mice per group). (C)
+
hi
+
hi
absolute number of CD11b CD11c DCs and CD11b F4/80 macrophages in
spleens of nonirradiated, 5, and 9 Gy irradiated mice. (D) mean fluorescent
intensity (MFI) of activating ligands on splenic DCs and macrophages. * =
p<0.05; ** = p<0.01; *** = p<0.001, Student t test.
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Lymphodepletion rapidly induces IL-12 family cytokine production by
dendritic cells
We next performed kinetic analysis of dendritic cells from non-myeloablated
and myeloablated mice to determine how long activated DCs remain present and
functional in the irradiated animal. To monitor function, we measured levels of IL12p40 (a subunit shared by both IL-12 and IL-23 (149)) in the serum of irradiated
mice. Although both 5 and 9 Gy TBI decrease the absolute number of splenic
CD11c+DCs in mice by day 3 (Figure 3-05A-B, open diamond), a robust and
transient increase in the absolute number of activated CD11chiMHCII+CD86hi DCs
was observed in irradiated mice within 6-24 hours post TBI (Figure 3-05A-B, black
square). Interestingly the peak of CD11chiMHCII+CD86hi DC activation was more
rapid in mice given a myeloablative (9 Gy + HSC) regimen than in mice given a
non-myeloablative (5 Gy) regimen (6 hrs versus 24 hours, respectively, see Figure
3-05A-B). Yet, IL-12p40 was detected within 6-12 hours in the serum of mice given
either TBI regimen (Figure 3-05C) but was significantly lower in non-irradiated mice
(0 Gy-basal is <100pg/ml, not shown). Moreover, significantly higher IL-12p40 was
detected in the serum of mice given a myeloablative preparative regimen than in
the serum from non-myeolablative mice.
Based on our finding that IL-12p40 was increased in the serum of irradiated
mice, we next looked at the direct capacity of DCs to secrete IL-12 and IL-23 after
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Figure 3-05. TBI rapidly activates dendritic cells in the spleen.

Splenic DCs were isolated from mice given (A) 5 Gy TBI or (B) 9 Gy (+HSC)
TBI 6, 12, 24, 48 and 72 hours after irradiation, and analyzed for expression of
CD11b, CD11c, CD86 and MHCII by flow cytometry. (C) IL-12p40 in serum from
non-myeloablated (5 Gy TBI) or myeloablated mice (9 Gy TBI + HSC) at 12
hours, 24 hours, and 48 hours following TBI by ELISA. Data representative of
three separate experiments. (D) Levels of IL-12 and IL-23 produced by dendritic
cells from spleens of mice receiving escalating doses of irradiation. One day
+
hi
post-irradiation, dendritic cells were sorted from splenocytes as CD11c CD86
from mice given 0, 5, or 9 Gy (+HSC) TBI, and dendritic cells were plated
overnight in cell media. After 18 hours, supernatant from cultures was collected
and analyzed via ELISA. Data are representative of 2 independent experiments
(n=4 mice per group). * = p<0.05; ** = p<0.01; one way repeated measures
ANOVA.
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Irradiation. As anticipated, DCs isolated from the spleen of myeloablated mice (9
Gy + HSC) secreted significantly more IL-12 and IL-23 one day following TBI than
DCs from 5 Gy irradiated and non-irradiated mice (Figure 3-05D). Moreover, the
amount of IL-12 and IL-23 secreted by DCs was proportionate to increases in TBI.
Macrophages also secreted IL-12 and IL-23 due to TBI but to a markedly less
amount than DCs (not shown). Our findings underscore that myeloablation
augments the function of host DCs, as demonstrated by their heightened secretion
of IL-12 and IL-23 compared to DCs from non-irradiated or non-myeloablated mice.

Lymphodepletion triggers changes in MDSC subsets in tumor-bearing mice
Pmel-1 T cells engineered to secrete IL-12 eradicate melanoma when
infused into mice (150), and one impact of

IL-12 signaling in the tumor

microenvironment is a programmatic change in dysfunctional myeloid-derived
suppressor cells to an inflammatory phenotype which enhances pmel-1 T cellmediated tumor regression (151, 152). Specifically, they found that IL-12
decreased monocytic CD11b+ Ly6ChiLy6Glo cells (MDSC-M) but increased
granulocytic CD11b+ Ly6Chi Ly6Ghi cells (i.e. MDSC-G) in the tumor (151). Thus,
as myeloablation (9Gy+HSC) increases IL-12 secretion by host DCs, we
rationalized that this regimen altered the MDSC-G and MDSC-M cell composition
in myeloablated mice compared to in non-irradiated mice. Using flow cytometry,
we examined the presence of these two MDSC subsets in the spleen of
lymphoreplete (0 Gy), non-myeloablated (5 Gy) or myeloablated (9 Gy + HSC)
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mice 12 hours after TBI. Indeed, the frequency and absolute number of splenic
MDSC-G cells was increased in myeloablated mice (9 Gy + HSC) over MDSC-M
cells compared to in non-irradiated mice or in mice given a non-myeloblative
regimen (Figure 3-06A-B). Yet, few of these subsets remained in the spleen, blood
or tumor of recipient mice 5 days post TBI. Moreover, we found that TBI transiently
induced MDSC-M but not MDSC-G cells to express a plethora of co-stimulatory
molecules, including CD86, CD70, CD80, 4-1BBL and ICOS ligand (Figure 3-07AB). Collectively, our data reveal that TBI alters the balance and activation status of
DCs, macrophages, MDSC subsets in vivo and hosts DCs from irradiated mice
secrete high quantities of IL-12 and IL-23.
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Figure 3-06. Granulocytic MDSCs are transiently increased over monocytic
MDSCs in tumor-bearing mice given TBI.

(A-B) Mice were conditioned with either no irradiation (0 Gy), non-myeloablative
5 Gy TBI, or myeloablative 9 Gy TBI with hematopoietic stem cells (HSC).
Twelve hours later, spleens from these mice were analyzed for the presence of
+
hi
lo
+
hi
hi
monocytic CD11b Ly6C Ly6G cells (MDSC-M) and CD11b Ly6C Ly6G cells
(i.e. MDSC-G). Data is representative of three experiments. ** = p<0.01; one way
repeated measures ANOVA.
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Figure 3-07. TBI increases activating ligands on MDSC-M but not
MDSC-G.
+

hi

lo

Co-stimulatory ligand expression of CD11b Ly6C Ly6G MDSC-M (A), and
+
mid
hi
CD11b Ly6CC Ly6G MDSC-G (B) in the spleens of mice receiving 0, 5, or 9
Gy irradiation 1 day prior to spleen harvest; n=3 mice per group; * = p<0.05, **
= p<0.01, *** = p<0.001, two tail t-test, error bars represent standard error.
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TBI-induced IL-12 augments the antitumor activity of transferred Tc17 cells
We next sought to determine if TBI-induced IL-12 or IL-23 cytokines were
responsible for the improved antitumor activity of the transferred pmel-1 Tc17 cells
in myeloablated mice. To do this, we neutralized IL-12 or IL-23 with IL-12p35 or
IL-23p19 (subunits distinctly expressed on IL-12 or IL-23, respectively) in mice preconditioned with a myeloablative therapy prior to infusion of pmel-1 Tc17 cells. IL12 appeared important for Tc17 cell-mediated tumor immunity in myeloablated
mice, as melanoma regression was appreciably compromised in mice given
neutralizing IL-12p35 antibodies compared to treatment groups given an isotype
control (Figure 3-08). Unexpectedly, despite the role of IL-23 as a key maintenance
signal for Th17 cell function and expansion (153), neutralizing this cytokine (IL23p19) did not impair Tc17 treatment in myeloablated mice nearly as much as IL12 depletion did (Figure 3-08). Additionally, IL-12 or IL-23 neutralization did not
impact treatment outcome in mice that were not infused with Tc17 cells (Figure 308). Our data suggest that TBI-induced IL-12, at least in part, augments Tc17 cellmediated tumor regression in myeloablated mice.

IL-12 and IL-23 distinctly regulate the functional plasticity, cytotoxicity and
transcription factor profile of adoptive transferred tumor-reactive Tc17 cells
Given that TBI-induced IL-12 augments pmel-1 Tc17 cell antitumor activity
in myeloablated mice (Figure 3-08), we surmised that if Tc17 cells were in vitro
primed with IL-12 they would effectively regress melanoma in mice and that these
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Figure 3-08. TBI induced IL-12 enhances the antitumor activity of Tc17 cells in
myeloablated mice more than IL-23.

B16F10 tumor bearing mice received 9 Gy TBI (+HSC) were either infused or
not with pmel-1 Tc17 cells. Mice were injected 0 and 24 hours post-transfer with
100 μg neutralizing antibodies against either IL-12p35 or IL-23p19 or IgG
isotype control; n=5 mice/group, ** = p<0.01, one way repeated measures
ANOVA.
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mice would require less lymphodepletion. We also posited that IL-12 would bolster
the functional plasticity of pmel-1 Tc17 cells in vitro, similar to that seen with pmel1 Tc17 cells from myeloablated mice (9 Gy TBI + HSC, Figure 3-03B). As
expected, IL-12-primed Tc17 cells were highly poly-functional, as 74% secreted
IL-17A, 52% secreted IFN- and 41% co-secreted IL-17A plus IFN- (Figure 309A). Conversely, IL-23-primed Tc17 cells maintained high IL-17A production
(66%) and suppressed IFN- (8%) (Figure 3-09A). In contrast to Tc17 cells, neither
IL-12 nor IL-23 priming enhanced the ability of pmel-1 Tc0 cells to co-secrete IL17A and IFN- (Figure 3-09A). These findings signify that IL-12 triggers the
functional plasticity of Tc17 cells in vitro, as demonstrated by their robust capacity
to co-secrete IL-17A and IFN-.
Tc0 cells are more cytotoxic than Tc17 cells in vitro (137). Thus, we next
sought to determine how IL-12 and IL-23 regulate the cytotoxicity of Tc0 versus
Tc17 cultures by measuring their release of Granzyme B. We found that priming
Tc0 cells with IL-12 or IL-23 only marginally increased the population of Granzyme
B/IFN- double producers (76% unprimed vs. 84% primed) and all Tc0 cultured
cells secreted high amounts of Granzyme B (Figure 3-09B). Unprimed Tc17 cells
by contrast expressed low basal levels of Granzyme B (20%), and priming with IL12 enhanced Granzyme B secretion (38%) with the majority of these cells also
producing IFN- (23 of 38%). Conversely, IL-23 did not induce Tc17 cells to
produce Granzyme B compared to unprimed Tc17 cells (22% vs. 20%) (Figure 3-
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Figure 3-09. IL-12 and IL-23 distinctly regulate the function, cytotoxicity and
transcriptional profile of Tc0 and Tc17 cells.

Flow analysis of Tc0 and Tc17 cells either unprimed or in vitro primed with IL-12
or IL-23 5-6 days post activation. (A) IL-17A and IFN-γ secretion by Tc0 and
Tc17 cells. (B) IFN-γ and granzyme B production by Tc0 and Tc17 cells. (C)
RORT and T-bet transcription factor expression. Results representative of 5
independent experiments. (D) Memory phenotype of pmel-1 Tc0 and Tc17
cultures based on CD44 and CD62L expression as analyzed by flow cytometry.
Data are representative of 4-5 independent experiments.
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09B). Thus, IL-12 increases the cytotoxicity of Tc17 cells, as revealed by their
marked gain in IFN- and Granzyme B production.
We next sought to investigate how IL-12 and IL-23 regulates the expression
of transcription factor RORt and T-bet in pmel-1 Tc17 cells. The transcription
factor T-bet is important for sustaining IFN- production by CD8+ T cells while
transcription factor RORγt is well known to promote IL-17A secretion by Tc17 cells
(154, 155). Using flow cytometry, we found that classic Tc17 cells expressed high
levels of RORt and nominal T-bet. Yet, IL-12 priming decreased RORt and
increased T-bet expression in Tc17 cells while IL-23 maintained RORt (Figure 309C). Conversely, Tc0 cells expressed nominal RORt and T-bet. IL-23 did not
induce RORt expression in Tc0 cells. However, IL-12 but not IL-23 significantly
increased T-bet expression in Tc0 cells (Figure 3-09C) which is not surprising,
given that IL-12 has been reported to induce T-bet in T cells (156). In summary,
IL-12 and IL-23 differentially regulate RORt and T-bet in antitumor Tc17 cells,
which likely explains why they co-secrete IFN- and IL-17A in myeloablated
animals (Figure 3-03B).
Given that TBI appeared to improve the memory response of Tc17 cells
based on the durable tumor eradication Tc17 cells induced in myeloablated
animals, , we wanted to determine if IL-12 promoted a shift in the Tc17 cultures
from a more differentiated effector (CD62LloCD44hi) memory phenotype to a less
differentiated central (CD62LhiCD44hi) memory phenotype (61). Tc17 cells
displayed an effector memory phenotype while Tc0 cells exhibited central memory
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profile, as previously reported (93, 137). Interestingly, IL-12 only increased the
frequency of central memory cells in the Tc0 but not Tc17 cell culture (Figure 309D). Collectively, our data reveal that priming Tc17 cells with IL-12 increases their
functional and transcriptional plasticity in vitro to a more inflammatory and cytotoxic
phenotype type. Yet, the potentiating effect of TBI on the persistence of Tc17 cells,
the longevity of their antitumor response, and their recall cytokine production to
antigen, cannot be explained by IL-12 induced CD62L expression, on Tc17 cells.

L-12 priming augments the antitumor potential of Tc17 cells by enhancing
trafficking and persistence
Given that TBI induces host DCs to secrete high IL-12 and IL-23 levels in
heavily pretreated mice (9 Gy TBI + HSC) (Figure 3-05), we assessed whether
priming Tc17 cells with IL-12 or IL-23 in vitro would augment their antitumor activity
in mice preconditioned with a lower intensity and less toxic level of
lymphodepletion (i.e. 5 Gy TBI). To address this idea, we transferred Tc17 cells
that were primed with IL-12 or IL-23 in vitro into melanoma tumor-bearing mice
conditioned with a non-myeloablative (5 Gy TBI) preparative regimen. As an in
vitro vaccination, pmel-1 subsets were re-stimulated with irradiated splenocytes
presenting hgp10025-33 peptide prior to transfer into recipient mice (131). Tc17 cells
primed with IL-12 mediated tumor regression to a greater extent than unprimed or
IL-23-primed Tc17 cells (Figure 3-10A-C). Importantly, this did not appear to be
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Figure 3-10. Pmel-1 Tc17 cells primed with IL-12 mediate potent antitumor
responses in vivo.

Ten million pmel-1 Tc17 cells were primed with either IL-12 or IL-23 in vitro then
transferred into mice bearing established B16F10 melanomas. Recipient mice
were irradiated with 5 Gy TBI 12 hours prior to adoptive transfer. No adjuvant
vaccination and no IL-2 support was administered. (A) Pmel-1 Tc17 cells that
were not primed with cytokines in the IL-12 family served as a control compared
to (B) IL-23 primed Tc17 cells, and (C) IL-12 primed Tc17 cells. Data
representative of 2 independent experiments and n=8 per group; * = p<0.05, **
= p<0.01, *** = p<0.001, one way repeated measures ANOVA.
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due to differences in the initial impact on tumor size, but rather an improved
capacity to exert tumor control for a longer period of time.
Because IL-12 appeared to increase the duration of tumor control by IL-12
primed Tc17 cells in non-myeloablated mice, we hypothesized this was due to an
increase in donor T cell numbers in tumor and spleen similar to the trend seen with
increasing the intensity of TBI. IL-12 priming augmented trafficking of pmel-1 Tc17
cells to the tumor over host CD8, CD4 or NK cells in myeloablated mice (Figure 311A). Interestingly, the combination of both host preconditioning with 5 Gy TBI and
priming Tc17 cells with IL-12 increased tumor infiltration of pmel-1 Tc17 cells over
host cells to ratios similar or greater than those seen in the tumors of 9 Gy
preconditioned hosts treated with Tc17 cells (Figure 3-11A). While IL-12 priming
also increased the engraftment of Tc17 cells in the spleens of 5 Gy preconditioned
hosts over non-irradiated hosts, donor levels were lower than in myeloablated
hosts (Figure 3-11B). Thus, while IL-12 priming Tc17 cells in vitro augments their
capacity to migrate to the tumor and regress melanoma in non-myeloablated mice
to levels seen in myeloablated mice, it cannot fully replicate the increased T cell
persistence in lymphoid tissues observed in fully myeloablated hosts.
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Figure 3-11. Priming Tc17 cells with IL-12 improves trafficking to the tumor but
does not increase their engraftment in the spleen.

Unprimed or IL-12 primed Tc17 cells were infused into mice with B16F10 tumors
conditioned with either no irradiation (0 Gy), non-myeloablative 5 Gy TBI, or
myeloablative 9 Gy (+HSC) TBI. (A) Relative infiltration of donor pmel-1 Tc17
+
+
cells to host CD8 T cells, host CD4 T cells, or host NK into tumors combined
from n=3 mice. (B) Ratios of donor Tc17 cells primed or not with IL-12 compared
+
+
to host CD8 , CD4 , and NK cells in the spleen by flow analysis on day 5 post
transfer; n=2-5 mice per group; *** = p<0.001, **** = p<0.0001, one way
repeated measures ANOVA.
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Exogenous IL-12 therapy replaces a myeloablative preparative regimen.
The robust antitumor response by IL-12 primed Tc17 cells in nonmyeloablated hosts prompted us to question if a low dose of IL-12 to non-irradiated
animals would entirely replace preconditioning the host with TBI. To answer this
question, Tc17 cells primed with IL-12 were transferred into non-irradiated mice
bearing B16F10 melanoma tumors. Mice were then either treated with or without
exogenous IL-12 or IL-23 (0.3μg, injected subcutaneously) one and seven days
post T cell transfer. Administration of exogenous IL-12 bolstered the antitumor
activity of IL-12-primed Tc17 cells in non-irradiated animals (Figure 3-12A).
Importantly, this treatment mirrored the antitumor activity of Tc17 cells transferred
into a myeloablated host (IL-12 primed Tc17 cells plus exo. IL-2 (open diamond) =
Tc17 cells in 9Gy condition (open circle), Figure 3-12A-B). Interestingly,
exogenous IL-23 treatment did not augment the antitumor activity of IL-12 primed
Tc17 cells (Figure 3-12A), despite its known role to promote the generation of
pathogenic Tc17 cells (157). We also found that exogenous IL-12 augmented the
antitumor activity of IL-12 primed Tc0 cells (Figure 3-12C) but not to the extent
achieved by IL-12 primed Tc17 cells (Figure 3-12A). Collectively, our data suggest
that to achieve curative responses in mice not only requires either myeloablative
TBI or exogenous administration of IL-12 and IL-12 priming of T cells, but still
requires the selection of T cells for therapy that are long-lived effectors such as
type 17 cells.
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Figure 3-12. Exogenous IL-12 mediates durable antitumor immunity in nonirradiated mice infused with IL-12-primed pmel-1 Tc17 cells.

(A) Unprimed or IL-12-primed Tc17 cells were adoptively transferred into nonirradiated tumor bearing mice with or without exogenous IL-12 or IL-23 cytokine
(0.3 μg/mouse subQ) on day 1 and 7 post-transfer. Mice receiving no treatment,
or only exogenous IL-12 but no T cells were used as controls. (B) Ten million
Tc17 cells were transferred into either non-irradiated or myeloablated (9 Gy +
HSC) tumor-bearing hosts. Mice receiving only myeloablative TBI with HSC
were used as controls. (C) Ten million IL-12-primed Tc0 cells were transferred
into non-irradiated tumor-bearing mice with or without exogenous IL-12
treatment. Data representative of 2 independent experiments and n=8 mice per
group; * = p<0.05, ** = p<0.01, *** = p<0.001, one way repeated measures
ANOVA.
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Discussion
Host preconditioning with lymphodepletion augments the antitumor activity
of infused IFN-+CD8+ T cells (Tc0) in mice and in humans with melanoma. Yet,
the extent to which lymphodepletion impacts the fate of antitumor IL-17A+CD8+ T
(Tc17) cells – an emerging subset showing great promise in ACT murine models—
remains unknown. To address this, we polarized pmel-1 CD8+ T cells to secrete
IL-17A or IFN- and infused them into melanoma-bearing mice that were either 1)
not lymphodepleted (0 Gy TBI) or lymphodepleted with 2) a non-myeloablative (5
Gy TBI) or 3) myeloablative (9 Gy TBI requiring HSC) preparative regimen. We
found that Tc17 cells regressed melanoma in myeloablated mice to a greater
extent than in lymphoreplete or non-myeloablated mice (Figure 3-1A-C).
Moreover, Tc17 cells but not Tc0 cells mediated curative responses in
myeloablated mice. Additional investigation revealed that Tc17 cells converted
from mainly IL-17A producers into IL-17A+IFN-+ double producers 2 days after
transfer into myeloablated mice and that these cells converted more rapidly in
myeloablated mice than in lymphoreplete or non-myeloablated mice (Figure 3-03).
Interestingly, lymphodepletion triggered the innate immune system, as
demonstrated by an increase in the number of dendritic cells, granulocytic MDSCs,
and macrophages before their disappearance (Figure 3-04 through 3-07). Among
these cells, dendritic cells showed significant increases in their co-stimulatory
ligand expression after irradiation (Figure 3-04) and rapidly secreted the proinflammatory cytokines IL-12 and IL-23 (Fig 3-05). Interestingly, only IL-12
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secreted by TBI-activated host DCs appeared to augment the plasticity and
antitumor activity of transferred Tc17 cells, as blocking endogenous IL-12 but not
IL-23 reduced the therapeutic efficacy of Tc17 cells in myeloablated mice (Figure
3-08). Conversely, priming Tc17 cells in vitro with exogenous IL-12 but not IL-23
enhanced their functional plasticity and capacity to regress melanoma in vivo
(Figure 3-09 and 3-10). Administration of low dose IL-12 to non-irradiated mice
further potentiated the antitumor activity of IL-12-primed Tc17 cells (Figure 3-12),
leading to long-term antitumor immunity in mice without the requisite for
lymphodepletion.
Given that IL-12 and IL-23 enhance immune responses to tumors (152, 158,
159) and because we found that both IL-12 and IL-23 are induced in myeloablated
mice (Figure 3-05), we suspected that these cytokines were important for
enhancing Tc17 cell-mediated tumor immunity in myeloablated mice. As expected,
blocking IL-12 with an antibody that neutralizes IL-12p35 impaired the antitumor
activity of Tc17 cells in myeloablated mice. Unexpectedly, blocking IL-23 with antiIL-23p19 did not impair treatment outcome in myeloablated mice infused with Tc17
cells (Figure 3-08). While suggestive that TBI-induced IL-12 but not IL-23 is
responsible for augmenting Tc17-mediated tumor regression in myeloablated
mice, we should proceed with caution with this interpretation. While neutralizing
IL-12p35 with this antibody impaired the antitumor activity of Tc17 cells in
myeloablated mice, it is worth noting that p35 is also part of the cytokine IL-35 (a
cytokine in the IL-12 family composed of p35 and EBI3 subunits) (160). Although
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our studies did not examine IL-35 production in irradiated animals, future studies
on the role of TBI on IL-35 would be interesting in the context of ACT therapy,
particularly given that IL-35 has been reported to promote cancer growth (161).
However, based on our findings, IL-12p35 has a positive therapeutic effect on Tc17
cells in vivo (Figure 3-08). Indeed, IL-12p35 has also been shown to be critical for
the secretion of IL-18 in vivo-which can also be key for inducing IFN production
by T cells (162-164). Thus, in future studies it would be of interest to know whether
blocking IL-12p35 prevents IL-18 secretion, thereby impairing IFN- production by
transferred Tc17 cells in myeloblated mice. Thus, while it would be worthwhile to
further delineate p35 for IL-12, IL-18 and IL-35 in myeloablated mice, the difficulty
due to overlap with these various cytokines is appreciated.
IL-12 induces toxic side effects in humans, which has hampered its
translation into the clinic (165). To circumvent these negative side effects of IL-12
in vivo, we sought to use IL-12 in pmel-1 Tc17 cultures to enhance their function
and cytotoxicity in vitro and then wash out IL-12 before infusing these cells into
mice. Via this approach, we found that priming Tc17 cells with IL-12 enhanced
their function and cytotoxicity in vitro and in vivo (Figure 3-09A-B) . Tc17 cells
primed with IL-12 greatly increased their IFN- production (52%) compared to
those primed with IL-23 (8%) (Figure 3-09A). Moreover, IL-12 primed Tc17 cells
secreted higher amounts of granzyme B (Figure 3-09B). This increase in classical
Tc1 effector molecules in Tc17 cells correlated with an induction of T-bet and
suppression RORt (Figure 3-09C). Along with modulating T-bet, IL-12 has been
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reported to convert Tc17 cells to IL-17A/IFN--double producers through
epigenetic suppression of cytokine signaling 3 (SOCS3) gene promoters (166,
167). Thus, future studies that investigate the role of how TBI regulates SOCS3 as
well as STAT signals in transferred Tc17 cells may shed light on their pronounced
plasticity and antitumor activity in myeloablated mice. When transferred into mice,
IL-12 primed Tc17 cells showed greater antitumor efficacy than IL-23 primed and
unprimed Tc17 cells, which we attribute to the increased poly-functionality seen in
vitro (Figure 3-09), and enhanced capacity to traffic to the tumor over host
elements in vivo (Figure 3-11). Collectively, our results indicate that the role TBI
induced IL-12 plays in enhancing Tc17 cell antitumor efficacy is in augmenting the
function, cytotoxicity and tumor trafficking ability of these cells in vivo.
We demonstrated that mice infused with IL-12-primed Tc17 cells that were
also treated with a low dose of exogenous IL-12 experienced durable antitumor
responses without the normal need for host preconditioning with lymphodepletion
(Figure 3-12A). However, these potent therapeutic results cannot be recapitulated
by either 1) administration of exogenous IL-23 given to mice infused with IL-12primed Tc17 cells or by 2) exogenous IL-12 given to mice infused with IL-12primed Tc0 cells. Our body of work herein underscores that while IL-12
conditioning potentiates the antitumor activity of any transferred CD8 + T cells, it is
a particularly potent strategy in combination with Tc17 cells. It is intriguing that IL12 signaling enhanced the potency and durability of the Tc17 antitumor response
without changing the effector memory phenotype of the cells to a less differentiated
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phenotype as seen in Tc0 cells, something that would indicate an improved
capacity to exert long-term immunity. Yet, both TBI and IL-12 did increase the
persistence of Tc17 cells in the mice, as well as increase their ability to secrete
IFN- following antigen re-stimulation, both of which are important indicators of a
memory T cell. It appears that IL-12’s impact on function and trafficking of the Tc17
cell complimented intrinsic memory properties of the Tc17 cells that allowed for
potent long-lived immune responses. The CD4+ counterpart of Tc17 cells (Th17
cells) are reported as having a stem memory phenotype and can exert this type of
durable antitumor response (85, 88). Future studies will further elucidate the true
memory capacity of these cells and what mechanisms drive this phenotype in
these cells.
In conclusion, it is worth considering the impact of TBI on models of
lymphodepletion, as many investigators use TBI to study lymphocyte engraftment
and immunity to foreign, self and tumor tissue (72, 168). Yet, the induction of
homeostatic expansion of the T cell compartment after TBI preconditioning cannot
be viewed as simply expanding to fill empty space as was previously thought (74).
We and others have reported that TBI induces a complex set of events, such as
microbial translocation (84), which beyond inducing homeostatic cytokine
production also increases inflammatory signaling including secretion of IL-12 and
IL-23 from activated DCs. We show that the multiple factors induced by TBI create
an exclusive environment primed to enhance the efficacy of adoptively transferred
T cells, particularly Tc17 cells.
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Chapter 4: Th17 cells are effector cells with durable memory capable of
tumor eradication after long-term expansion

Introduction
Adoptive T cell therapy (ACT) achieves remarkable outcomes for patients
with objective responses of 54% and complete remissions of 24% (27, 169, 170).
To accomplish durable results in patients, ACT requires the infusion of large
numbers of tumor-reactive T cells (~1010 cells) (23-25, 33, 71, 171, 172). Most
protocols for generating vast T cell numbers require their expansion for up to three
months with at least one CD3-dependent re-activation (33, 71, 172). Yet, ex vivo
expansion works in direct opposition to maintaining antitumor efficacy because the
cytotoxic CD8+ T cells used in clinical trials lose their potency when extensively
expanded ex vivo. This loss of antitumor efficacy is due to a reduced capacity to
persist in vivo once CD8+ T cells reach terminal differentiation (46). Additionally,
this effect occurs rapidly, as even highly potent IL-12-primed CD8+ T cells lose
antitumor efficacy in as little as one week of expansion (173). Rapid-expansion
protocols also compromise the integrity of human tumor infiltrating lymphocytes
(TILs), while TILs that undergo shorter expansion ex vivo persist longer (49, 5355).
Although investigators have developed strategies to prevent T cell
differentiation ex vivo (60, 121), another potential avenue is to circumvent this
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dilemma using a T cell subset relatively refractory to in vitro expansion induced
senescence. In murine models of melanoma, TRP-1 Th17 cells (CD4+ T cells
which express the transcription factor RORt and secrete IL17), offer an alternative
to melanoma-reactive pmel-1 CD8+ T cells as they mediate a potent response
against aggressive melanoma in mice even without antigen vaccination and in vivo
IL-2 support required in pmel-1 CD8+ ACT models (93-95). This remarkable Th17
antitumor response occurs in part by enhancing CD8+ T cell responses against
transformed cells (97, 174-176) and via their ability to directly lyse tumor (177,
178). In both cases, Th17 cells exert superior antitumor immunity compared to Th1
and other CD4+ T cell subsets (93), as well as superior enhancement of CD8+ T
cells (97). Also, since Th17 cells show durable effectiveness in vivo and have stem
memory properties (85, 88), we posited that unlike CD8+ T cells, Th17 cells would
retain their antitumor capacity even after long-term ex vivo expansion to clinically
relevant doses.
We found that even without a rapid expansion protocol (REP), Th17 cells
were capable of robust growth for 21 days ex vivo yielding ~5,000 times the initial
CD4+ T cell numbers. Additionally, while exhibiting a CD44 hiCD62Llo effector
memory phenotype, Th17 cells expressed nuclear Tcf7 throughout in vitro culture
indicating active and preserved stem memory signaling. Unlike Th1 or CD8 + T
cells, Th17 cells retained their ability to eliminate melanoma tumors over two
weeks of expansion. Th17 cells were resistant to senescence indicated by
retention or upregulation of CD127, CD28 and CD27 along with nominal
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expression of KLRG1 and TIM3. In contrast, Th1 cells expressed exhaustion
markers and higher levels of checkpoint receptors and were far more apoptotic
than Th17 cultures at any time point of expansion. Importantly, Th17 cells
expanded for either a 7- or 21-day duration ex vivo were equally able to persist in
the tumor-bearing host after transfer. Despite similar antitumor potency between 7
and 21 day Th17 cells on a per cell basis, we hypothesized that mediating curative
responses in mice with large, nearly terminal, tumors would require the full yield of
Th17 cells generated from three weeks of culture. We found that treatment with
two or three week expanded Th17 cells rapidly and completely eradicated
aggressively growing tumors, while the full yield of one week expanded Th17 cells
was insufficient to control these tumors. Of clinical significance, human Th17polarized CD4+ cells also exhibit marked durability in antitumor potency compared
with Th1-polarized cells when expanded for either 7 or 12 days. Our analysis of all
parameters of Th17 cell ex vivo preparation for ACT (in vitro time of expansion,
cell yield, T cell subset, and size of tumor) indicate tumor-reactive Th17 cells
represent a cell product that can be reliably applied to treat highly aggressive solid
tumors.
ACT with Th17 cells still requires transferring large numbers of T cells to
clear tumors
The effectiveness of ACT is thought to depend on the transfer of large
numbers of tumor-specific T cells (46). Yet, because Th17 cells mediate potent
antitumor responses in mice and have durable stem memory properties, we
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hypothesized that we could titrate down the number of Th17 cells infused into mice
without impairing tumor clearance. To test this idea, TRP-1 transgenic CD4+ T cells
with a TCR specific for tyrosinase related protein-1 (TRP-1, a shared
melanocyte/melanoma antigen) were polarized to a Th17 phenotype and
expanded ex vivo for one week. This protocol generated cells with expression of
the Th17 transcription factor RORt, high IL-17 production, and nominal Tbet (the
Th1 transcription factor) and IFN (Figure 4-01A-B). We infused decreasing doses
of Th17 cells (4.5, 1.5 or 0.5e6 cells/mouse) into C57BL/6J mice with established
B16F10 melanoma preconditioned with non-myeloablative (5 Gy) total body
irradiation (TBI) (Figure 4-01C). While the highest number of Th17 cells (4.5e 6)
eliminated tumor in most mice, tumor responses and overall survival declined in
mice treated with fewer Th17 cells (Figure 4-01C-D). Thus, despite their enhanced
antitumor efficacy and a stem memory profile, Th17 cells require a sufficient
number of transferred cells for successful ACT.

77

Figure 4-01. High numbers of transferred Th17 cells are required for successful
antitumor response.

(A) Rort and Tbet expression by Th17 cells after 7 days of culture;
representative of 3 independent experiments. (B) IL-17A and IFN expression
by Th17 cells after 7 days of culture; representative of 5 independent
experiments. (C) Th17 cells cultured ex vivo for 9 days were administered to
mice with B16F10 melanoma after non-myeloablative (5 Gy) total body
irradiation (TBI) one day prior to treatment with the indicated Th17 cell doses;
n=6-7 mice/group, representative of 3 independent experiments. (D) Percent
6
survival of mice treated with 4.5, 1.5 or 0.5e Th17 cells/mouse. Kaplan Meier
curves compared by log rank test; * = p<0.05.
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REP decreases the antitumor capacity and recall responses of Th17 cells
Since large numbers of Th17 cells are required to eradicate tumors, we
tested whether extending in vitro culture time for another week using a rapid
expansion protocol (REP) with TCR re-activation would improve their yield. To test
this, as presented in Figure 4-02A, Th17 cells were expanded for two weeks with
the REP culture undergoing TCR re-activation using TRP-peptide pulsed feeder
cells at one week. Interestingly, Th17 cells only activated once (primary expansion)
could effectively expand for two weeks to similar yields as REP Th17 cells (Figure
4-02B). By day 14, both Th17 and REP Th17 cells were mainly CD44hiCD62Llo
effector memory (Figure 2C). However, REP Th17 cells were slightly compromised
in their ability to regress tumors and promote survival in mice (Figure 4-02D-E).
The decreased antitumor efficacy of REP Th17 cells was not due to
increased levels of apoptosis, KLRG1, PD1 or TIM3 compared to Th17 cells
(Figure 4-03A-C). Yet, while the frequency of donor Th17 cells in the spleen and
tumors of surviving mice was similar to the frequency of REP Th17 cells 40 days
post-treatment (Figure 4-03D-E), memory recall against TRP-1 antigen by mice
treated with REP donor Th17 cells was significantly impaired compared to mice
treated with Th17 cells in an in vivo cytotoxic assay (Figure 4-03F). Thus, rapid
expansion protocols appear to compromise the antitumor efficacy and antigen
recall responses of donor Th17 cells.
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Figure 4-02. REP does not improve Th17 yield and reduces antitumor efficacy.

(A) Schematic for growth of Th17 and REP Th17 cultures. (B) Yield of Th17 and
REP Th17 cells after two weeks of culture, representative of 3 independent
cultures. (C) CD44 and CD62L memory marker expression on Th17 or REP
Th17 cells on day 15, n=3 independent cultures. (D) Mice with B16F10 were
6
treated with 2e Th17 cells or REP Th17 cells after 5 Gy TBI; n=10 mice/group,
representative of 2 independent experiments. (E) Percent Survival of cohorts
treated with Th17 or REP Th17 cells; Kaplan Meier curves compared by log rank
test; ns = not statistically significant.
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Figure 4-03. REP protocol does not induce senescence or apoptosis in Th17 cells
but does impair antigen recall responses.

(A) Propidium iodide (PI) and Annexin V staining on two week expanded Th17
and REP Th17 cells with or without 12 hour incubation with anti-CD3 antibody;
n=3 cultures.
(B) KLRG1 and PD1 expression on Th17 and REP Th17 cells
after two weeks; n=3 cultures. (C) KLRG1 and TIM3 expression on Th17 and
REP Th17 cells after two weeks; n=3 cultures. (D) Mean frequency ( SEM) of
donor Th17 or REP Th17 cells in spleen of treated mice; n=5-8 mice/group. (E)
Mean frequency ( SEM) of donor Th17 or REP Th17 cells in tumor of treated
mice with mean; n=5 mice/group. (F) Memory response of donor Th17 or REP
Th17 cells evaluated by an in vivo cytotoxicity assay reported as mean percent
specific lysis ( SEM); n=5-8 mice/group. Mean frequency and percent specific
lysis compared by student’s t-test; ns= not statistically significant, ** = p<0.01.
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Th17 cells become less activated but not terminally differentiated during ex
vivo expansion
We next sought to determine how long Th17 cells could be expanded in
vitro without losing antitumor efficacy. We found that Th17 cells could expand for
three weeks without TCR re-activation (Figure 4-04A). While tyrosinase-specific
(V14+) CD4+ T cells have a naïve phenotype (CD44loCD62Lhi) when isolated from
the spleens of TRP-1 mice, Th17 cells exhibited an effector memory phenotype
with high CD44 and low CD62L expression as early as one week after activation,
which prevailed throughout culture (Figure 4-04B). This phenotype corroborates
previous studies with human and murine Th17 cells which found Th17 cells exerted
long-lived immunity despite an effector memory phenotype (88, 93).
Because we were not using a REP protocol to expand the Th17 cells, we
expected that the cells would gradually become quiescent and down-regulate
activation markers as they were expanded for 21 days in vitro. As expected,
activation markers CD69 and CD25 (IL-2R) were initially high one week after
stimulation but progressively declined (Figure 4-04C). Similarly, Th17 cells initially
expressed high levels of ICOS, which is an important co-stimulatory molecule that
supports their function and maintenance (94, 179), while the co-stimulatory
receptor 4-1BB was only increased moderately above pre-activation levels one
week after activation. In contrast, CD127 (IL-7R) was maintained on Th17 cells
expanded for 3 weeks. As CD127 is expressed on naïve and memory cells (72),
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Figure 4-04. Th17 cells expanded for three weeks enter quiescence while
maintaining or upregulating memory markers.

(A) Growth of Th17 cells in culture; n=7 independent cultures. (B) CD44 and
+
+
CD62L memory marker expression on V14 CD4 T cells before polarization
and Th17 cells at different time-points in culture via flow cytometry;
representative of 3-5 cultures (C) Mean MFI ( SEM) of cytokine and costimulatory receptors during ex vivo culture of Th17 cells assessed by flow
cytometry; n=5 independent cultures.
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this not only suggests a persistent responsiveness to IL-7 (73), but also a
persistent memory phenotype. The costimulatory ligand CD28 was similarly
retained through culture, while CD27, which is associated with adaptive memory
responses (180), increased between week 1 and week 3 (Figure 4-04C).
Importantly, the retention of CD127 and CD28, and the increased expression of
CD27 during expansion, may indicate that Th17 cells are resistant to the
senescence that naturally occurs in other T cells subsets (181).

Long-term expanded Th17 cells retain antitumor potency
We next tested whether the pattern of chemokine and co-stimulatory
receptor expression we observed throughout culture truly indicated a preserved
memory phenotype and antitumor capacity. We posited that Th17 cells (in contrast
to CD8+ T cells (46)) would retain antitumor activity as they expanded long-term in
vitro. To compare Th17 cell antitumor efficacy over ex vivo culture time on a per
cell basis, Th17 cells were expanded for three weeks with a portion of cells
cryopreserved at either 1) early (day 6-7), 2) intermediate (day 12-14), or 3) late
(day 18-21) time points in culture. Th17 cells were then transferred at equal
numbers (2e6 Th17 cells/mouse) from each time-point into lymphodepleted mice
bearing established melanoma. Note that for late Th17 culture, the infusion product
represented a mere 1/2500th of their total cell count. Yet, no matter the duration of
in vitro expansion, Th17 cells killed tumors (Figure 4-05A) and supported longterm survival (Figure 4-05B) in the majority of mice.
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Figure 4-05. Th17 cells expanded for three weeks retain capacity to eliminate
tumors.
6

(A) Mice with B16F10 tumors were treated with equal numbers (2e
cells/mouse) of Th17 cells from the early, intermediate and late time-points of
ex vivo culture following 5 Gy TBI one day prior; n=8-9 mice/group,
representative of 4 independent experiments. (B) Percent survival of mice
treated in panel A; n=8/9 mice/group, Kaplan Meier curves compared by log
rank test; ns = not statistically significant.
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Th17 cells persist in the host and preserve telomere length and wnt/catenin signaling regardless of in vitro expansion time
T cell persistence correlates with enhanced treatment outcome in
melanoma patients given ACT (53). Thus, the similar antitumor efficacy mediated
by early or late culture Th17 cells in mice suggested that these cells – regardless
of time in vitro – would engraft and persist in mice at similar levels. To test this
idea, we followed donor TRP-1 CD45.2+ Th17 cells expanded for 7 (early) or 21
days (late) in CD45.1+ recipient mice over 28 days. Early and late Th17 cells were
present at equivalent numbers post-treatment at 7, 14, and 28 days in the spleen
and after 7 days in the tumor (Figure 4-06A). The eye is a common off-site target
for T cell models specific for melanocyte-associated antigens (i.e. tyrosinase)
because of melanocytes in the pigment epithelium (182). Here, too, we detected
early and late Th17 cells at comparable amounts in melanoma-bearing mice
(Figure 4-06A).
In ACT clinical trials, a donor T cells with longer telomeres persist better in
melanoma patients and is associated with improved survival (54, 55). We
hypothesized that preserved telomere length during expansion both in vitro and in
vivo might be a mechanism by which Th17 cells, at any stage of expansion,
preserved their antitumor efficacy after in vitro expansion. Telomere length only
slightly decreased in Th17 cells as they expanded in vitro (Figure 4-06B). Yet, both
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Figure 4-06. Th17 cells possess the memory cell characteristics of persistence,
telomere preservation and maintained Tcf7 expression.

(A) Mean number ( SEM) of donor Th17 cells from early or late culture timepoints in host C57BL/6 spleen, tumor and eye at indicated days post-treatment;
n=4-5 mice, representative of 2 independent experiments. Mean cell numbers
of early or late Th17 cells compared by student’s t-test; ns= not statistically
significant. (B) hybridized telomere PNA in Th17 cells at early and late culture
time-points; n=3 independent cultures. (C) Mean MFI ( SEM) of telomere
length in donor Th17 cells 4 weeks post-treatment; n=5 mice/group. Mean
telomere MFI compared by student’s t-test; ns = not statistically significant. (D)
Western blot analysis of nuclear protein from 7, 14, and 21 day expanded Th17
cells, T= Tcf7, H= Histone H3; representative of 4 independent cultures. (E)
Quantified Tcf7 protein relative to Histone H3 (Mean  SEM), RR (OD) = relative
ratio of optical density; n=4 independent cultures; one way repeated measures
ANOVA, ns = not statistically significant, ** = p<0.01.
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Th17 cells from early and late cultures maintained comparable telomere length
four weeks post ACT (Figure 4-06C).
Despite their persistent CD44hiCD62Llo effector memory phenotype, we
hypothesized that because of their persistence, long-lived immune responses
against tumor, and preserved telomeres, Th17 cells must have stem cell like
memory similar to stem memory T (Tscm) cells (60, 64). Indeed, Th17 cells
expressed Tcf7, a downstream product of active -catenin signaling throughout
culture (Figure 4-06D-E); the same stemness signaling described in Tscm cells
(60), and also implicated in memory T cell self-renewal and persistence (183).
Thus, a partial explanation for the durable antitumor response of Th17 cells may
be their maintenance of telomere length in vitro and in vivo, as well as continued
wnt/-catenin signaling.

Th17 cells undergo polyfunctional conversion during expansion but do not
change their interaction with host immune cells
We noticed that even without inflammatory signaling such as IL-12, which
drives Th17 cell conversion to a Th1-like phenotype (termed Th17 plasticity (166,
184, 185)), Th17 cells became progressively poly-functional. As seen by ELISA
performed 18 hours after peptide-dependent re-activation, IL-17A and IL-17F
decreased in concert throughout culture, IL-22 was lost rapidly after one week, and
IL-2 and IFN production increased during ex vivo expansion (Figure 4-07A). This
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Figure 4-07. Th17 cells undergo polyfunctional conversion in vitro but preserve
Th17 transcription factors.

(A) Cytokine production by Th17 cells from each time-point in culture analyzed
via ELISA 18 hours after TRP peptide stimulation (mean  SEM); n=5. (B)
Western blot of nuclear protein extracts from 7, 14, and 21 day expanded Th17
cells, R=RORt, S3= Stat3, S1= Stat1, H = Histone H3; representative of 4
independent cultures. (C) Quantified protein levels relative to Histone H3, RR
(OD) = relative ratio of optical density; n=4 independent cultures.
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correlated with reduced levels of nuclear Rort and STAT3, although both
molecules persisted throughout culture (Figure 4-07B-C). Additionally, Th17 cells
maintained nuclear STAT1, while Tbet was not detected (Figure 4-07B-C).
We suspected that the increased polyfunctionality of 3 week expanded
Th17 cells compared to 1 week old counterparts would increase the recruitment of
host CD8+ cells. In contrast, we found that mice treated with 21 day expanded
Th17 cells surprisingly had slightly fewer (though not statistically significant) host
CD8+ cells in the spleen and eyes of recipient CD45.1 +mice, indicated by their
higher ratio of donor Th17 to host cells (Figure 4-08A-B).
These differences between early and late Th17 cells, as well as previous
data showing Th17 cells enhance tumor specific CD8 + T cell immunity (97) led us
to question if early or late Th17 cells utilize endogenous CD8 + T cells to a different
degree in their antitumor response. We transferred early or late Th17 cells and
antibody depleted CD8+ T cells to address this question. Interestingly, all groups
had similar antitumor responses and survival rates (Figure 4-08C-D) suggesting
that Th17 cells are capable of tumor lysis independent of CD8 + T cells. However,
one should be conservative with this conclusion as other reports suggest depleting
host T cells might be beneficial to ACT therapy by removing competition for
homeostatic cytokines (82) which may have confounded the results. Thus, while
long-term expanded donor Th17 cells undergo functional conversion, they recruit
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and interact with host CD8+ T cells in tumor-bearing mice comparably to infused
Th17 cells expanded for 7 days in vitro.
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Figure 4-08. Polyfunctional conversion of Th17 cells in vitro does not change
+

interaction with host CD8 cells between early and late Th17 cells.
+

Ratio of donor Th17 cells to host CD8 T cells in (A) spleens and (B) eyes of
treated mice (mean  SEM); n=5 mice/group. (C) Mice with B16F10 tumors
5
were treated with 6e cells/mouse of early or late Th17 cells after 5 Gy TBI one
day prior. Starting the week of transfer mice received weekly CD8 depleting
antibody or isotype control antibody; n=10 mice/group. (D) Percent survival of
mice treated in panel C; n=10 mice/group, Kaplan Meier curves compared by
log rank test; ns = not statistically significant.
92

Th17 cells but not Th1 cells resist senescence and apoptosis in vitro
We next tested whether TRP-1 Th1 cells, like TRP-1 Th17 cells, could retain
their antitumor efficacy after long-term ex vivo expansion. While Th17 cells cleared
tumors similarly after one or two weeks of expansion, two-week expanded Th1
cells lost their ability to control tumor growth (Figure 4-09A-B). This is similar to the
loss of antitumor efficacy by CD8+ T cells which we found occurs in IL-12-primed
pmel-1 CD8+ T cells even without REP. Expanding these cells for only 10 days still
caused a dramatic reduction in antitumor activity compared to 4 day expanded
CD8+ T cells (Figure 4-10A-B). Note that the CD8+ T cells lost control of tumor
even after in vitro activation (a substitute for antigen vaccination (131)) and posttransfer injections of high dose IL-2, which were not used in either our Th17 or Th1
therapies.
To understand why Th17 and not Th1 cells had durable antitumor efficacy
during expansion, we surveyed expression of memory and other surface markers
as well as levels of apoptosis in culture overtime. Th1 cells had a significant cohort
of central memory cells at one week of culture compared to Th17 cells, indicated
by their CD62L expression (32% on Th1 vs. 4% on Th17). However, by the second
week, CD62L decreased on Th1 cells by half (Figure 4-11A). Thus, CD62L
expression on Th1 cells appears to correlate with their antitumor potential similar
to CD8+ T cells.
Unlike Th17 cells, Th1 cells maintained CD69 and CD25 expression
between day 7 and day 14. Yet, importantly, levels of CD25 on early Th1 cells were
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Figure 4-09. Th1 cells do not retain antitumor efficacy as they expand.

(A) Tumor burden of mice treated with one or two week expanded Th17 or Th1
cells compared to no treatment; n=10-16 mice/group, combined from 2
independent experiments. (B) Percent survival of mice treated with one or two
week expanded Th17 or Th1 cells compared to no treatment; n=10-16
mice/group, combined from 2 independent experiments; Kaplan Meier curves
compared by log rank test; ns = not statistically significant, * = p<0.05.
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+

Figure 4-10. CD8 T cells rapidly lose antitumor efficacy even without REP.

(A) Mice with B16F10 melanoma were irradiated with 5 Gy TBI then treated the
6
+
following day with 2e IL-12-primed pmel-1 CD8 T cells cultured for 4 or 10
days; n=12-15 mice/group; representative of 3 independent experiments. (B)
+
Percent Survival of mice treated with IL-12-primed CD8 T cells from 4 days in
culture or 10 days compared to no treatment mice. Kaplan Meier curves
compared by log rank test; **** = p<0.0001.
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Figure 4-11. Th17 cells are resistant to senescence during ex vivo expansion
compared to Th1 cells.

(A) CD44 and CD62L on Th17 and Th1 cells expanded for one or two weeks in
vitro, n=3 independent cultures. (B-C) Mean MFI ( SEM) of extracellular
receptors during ex vivo culture of Th17 and Th1 cells assessed by flow
cytometry; n=4 independent cultures.
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lower than on early Th17 cells indicating a reduced capacity to respond to the
homeostatic cytokine IL-2. Similarly, Th1 cells also had less CD127 than Th17 cells
(Figure 4-11B). We assayed the levels of other markers that along with
homeostatic cytokine receptor levels, can indicate T cell fitness (181, 186). We
observed that levels of CD28 were lower on early Th1 cells compared to early
Th17 cells, and CD27 expression decreased on Th1 cells between day 7 and day
14 in contrast to Th17 cells (Figure 4-11C). Additionally, KLRG1 and the
checkpoint inhibitor TIM3 were higher at each timepoint on Th1 cells versus Th17
cells. Interestingly, PD1 expression on early Th17 and Th1 cells was similar, but
expression of this inhibitory molecule declined by day 14 on Th17 cells while it
increased on Th1 cells (Figure 4-11C).
An important difference between Th1 and Th17 cells is their tendency to
undergo apoptosis and necrosis in culture. At day 7 ex vivo, 18% of Th1 cells were
single positive for Annexin V (indicating early entry into apoptosis), while 42%
stained positive for propidium iodide (PI) (indicating either the end stages of
apoptosis or necrosis). On the other hand, only 2% of Th17 cells were Annexin V
single positive or PI positive (Figure 4-12A). By day 14, 18% of Th1 cells were
Annexin V single positive and 3% were PI positive, while Th17 cells had 4%
Annexin V single positive and no PI positive cells (Figure 4-12A). However, Th1
cells demonstrated much more sensitivity to activation induced cell death than
Th17 cells. Twelve hours after TCR engagement with an anti-CD3 antibody we
observed up to 55% of Th1 cells were Annexin V single positive and 8% PI positive.
97

Figure 4-12. Th1 cells are more sensitive to apoptotic stress and express higher
levels of senescence markers than Th17 cells regardless of activation status.

(A) Propidium Iodide (PI) and Annexin V staining on one or two week expanded
Th17 and Th1 cells. Day 14 Th17 and Th1 cells were either incubated with
1g/mL anti-CD3 for 12 hours or left as an untreated control; n=3 independent
cultures. (B) Percent Annexin V single positive Th17 or Th1 cells (graphed with
mean  SEM) at two weeks expansion with or without reactivation. Reactivated
Th17 and Th1 cells were incubated with 10 Gy irradiated B6 splenocytes with
1M TRP-1 peptide for 18 hours; n=4 independent cultures. (C) Mean MFI (
SEM) of extracellular receptors during ex vivo culture of Th17 and Th1 cells
assessed by flow cytometry; n=4 independent cultures.
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Yet, Th17 cells remained resistant to apoptosis upon reactivation, demonstrated
by only slight increase in Annexin V staining from 4% to 8% on these cells (Figure
4-12A). We observed a similar pattern of increased annexin V+ cells in Th1 cells
but not Th17 cells after TRP-1 and irradiated splenocyte activation (Figure 4-12B).
To determine if expression of exhaustion/checkpoint molecules was merely
an artifact of activation, we activated day 14 Th17 and Th1 cells using irradiated
splenocytes bearing TRP-1 peptide. While CD69 expression increased
significantly on Th17 cells, KLRG1 did not, and TIM3 and PD1 only increased
marginally. However, expression of all these markers was higher on Th1 cells
compared to Th17 cells with or without activation and was not affected by
activation status (Figure 4-12C). Collectively, or data indicate that Th17 cells
maintain durable memory responses after long-term expansion in part, because of
their resistance to senescence and apoptosis, which may explain their improved
ability to regress tumors compared to Th1 or CD8+ T cells.

Large numbers of Th17 cells cure mice with aggressive tumors
Up to this point, we tested the antitumor capacity of Th17 cells expanded
for 1 to 3 weeks on a per cell basis. This ignored the vast expansion of these cells
by the end of 3 weeks of ex vivo expansion. We hypothesized that more Th17 cells
(>1e7 million) would be required to ablate large tumors and therefore would
necessitate long-term expansion. We therefore capitalized on the high yield of
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Th17 cells, which still had remarkably preserved effector potency, to regress large,
recalcitrant melanoma. To obtain differentially ‘aged’ Th17 cell products and test
their potential against large tumors, parallel cultures were grown from one Th17
polarization to early (day 7), intermediate (day 14) or late (day 18) time-points,
cryopreserved, and then split evenly among 12 mice/group. This protocol yielded
mean treatment doses of 1.3e6, 9.9e6 or 1.3e7 cells/mouse, respectively to treat
mice with large melanomas (~136 mm2) (Figure 4-13A). As anticipated, we found
that tumors regressed rapidly in mice treated with the high numbers of Th17 cells
from either the intermediate or late cultures (Figure 4-13B). This was evidenced by
the tumors in these mice reaching peak size earlier and having a smaller peak
tumor size than mice treated with early Th17 cells (Figure 4-13C-D). Conversely,
mice treated with 1.3e6 early Th17 cells were unable to control tumor growth with
most mice succumbing to disease (Figure 4-13B&E).

Infusing more Th17 cells from long-term expansion sets up long-lasting
memory and protection against multiple re-challenges.
A common correlate in successful adoptive immunotherapy for melanoma
is induction of autoimmune vitiligo after treatment (187). Thus, the reduced
antitumor efficacy of early Th17 cells was paralleled by a delay in onset of
autoimmune vitiligo (Figure 4-14A) indicating a weaker initial immune response.
However, all mice given Th17 cells (at any amount or at any age) eventually
developed a similar degree of vitiligo (Figure 4-14B). The correlation between
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Figure 4-13. Successful Th17 cell ACT against large tumors requires the cell
numbers achieved by long-term ex vivo expansion.

(A) Mean ( SEM) number of Th17 cells administered to mice with large
2
(median 136 mm ) B16F10 tumors from parallel cultures expanded to either
early, intermediate, or late culture time-points and divided among 12
th
th
mice/culture. Box = 25 to 75 quartiles, bars = min and max values; n=2
cultures. (B) Tumor control in mice treated with early, intermediate or late culture
Th17 cells; n=12 mice/group, representative of 3 independent experiments. (C)
Mean time ( SEM) in days post-treatment until tumors reached peak size
2
(mm ); n=12 mice/group. One way repeated measures ANOVA; *** = p<0.001.
2
(D) Mean ( SEM) peak tumor area (mm ) in each mouse before onset of tumor
control; n=12 mice/group. One way repeated measure ANOVA; * = p<0.5. (E)
Percent survival of mice treated with early, intermediate or late culture Th17
cells; n=12 mice/group, representative of 3 independent experiments. Kaplan
Meier curve compared by log rank test; ns = not statistically significant, *** =
p<0.001.
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Figure 4-14. Infusing large numbers of Th17 cells after two or three weeks of
expansion sets up long-term donor residence with enhanced memory response
against antigen and tumor re-challenge.

(A) Onset of vitiligo in treated mice for each group; n=12 mice/group. Kaplan
Meier curve compared by log rank test; ns = not statistically significant, ** =
p<0.01.
(B) Clinical scores of vitiligo in mice from early, intermediate, and
late Th17 cell treatment group after tumor resolution (mean  SEM); n=12
mice/group. One way repeated measures ANOVA; ns = not statistically
significant. (C-D) Mean frequency ( SEM) of donor Th17 cells in (C) spleens
and (D) draining lymph node (dLN) of surviving mice 40 days post-treatment;
n=5 mice/group. One way repeated measures ANOVA; * = p<0.05, ** = p<0.01.
(E) Memory recall assessed by in vivo lysis of peptide-pulsed splenocytes 40
days post-treatment compared to control mice (mean percent specific lysis 
SEM); n=5 mice/group. One way repeated measures ANOVA; ** = p<0.01.
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slower onset of vitiligo (Figure 4-14A) a slower halt of tumor growth (Figure 4-13CD) and subsequent loss of tumor control (Figure 4-13B) by early Th17 cells
compared to intermediate and late Th17 cells indicates that a strong and rapid
immune response, which is ensured by high numbers of infused effector T cells, is
crucial to a successful therapy.
We suspected that transferring more T cells would correlate with higher
numbers of memory T cells. As expected, higher frequencies of donor Th17 cells
were detected in the spleen and tumor draining lymph nodes (dLN) of mice infused
with more Th17 cells (intermediate and late cultures) (Figure 4-14C-D). This
correlated with stronger antigen recall responses, as mice treated with
intermediate and late Th17 cells had significantly higher rates of TRP-1 antigenpulsed cell lysis than early Th17 cell treated mice (Figure 4-14E).
Since the tumor control and antigen recall responses between intermediate
and late Th17 cell treated mice were similar, we further tested if treatment with
intermediate or late Th17 cells yielded the same antitumor immunity by
administering a second dose of subcutaneous B16F10 to the cured animals.
However, all animals from both treatment groups were protected from re-challenge
(Figure 4-15A), underscoring the therapeutic ability of Th17 cells to mediate
durable tumor immunity. To further test the potency of this therapy, we rechallenged the mice again with a more aggressive metastatic model. B16F10
tumor

cells

were

administered

intravenously to

mice

to

induce

lung

psuedometastases, which are far more challenging to treat than the subcutaneous
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Figure 4-15. Long-term expanded Th17 cells exert memory responses against
multiple B16F10 re-challenges.

(A) Average tumor burden of treatment groups after subcutaneous re-challenge
6
with 0.4e B16F10 compared to no treatment (mean  SEM); n=2-6 mice/group.
(B) Macroscopic images of lungs and high power microscopic images of
representative en-bloc sections from intermediate or late Th17 treated mice
6
compared to control mice 21 days after re-challenge with 0.2e B16F10 cells
injected IV n=2-6 mice/group. Scale bars for top right box = 120M. Scale bars
for bottom right box = 175M. (C) Quantification of percent of lung taken up by
tumor as determined by microscopic examination (mean  SEM); n=2-6
mice/group. Mean percent area compared by one-way repeated measures
ANOVA; **** = p<0.0001.
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tumors. Despite causing aggressive tumor outgrowth in the lungs of control mice,
the lungs of all mice previously treated with either intermediate or late Th17 cells
were protected from metastasis (Figure 4-15B). We performed histological
analysis of the lungs to confirm our macroscopic observations of no metastatic
tumor growth. Stepped sections were cut through whole lung blocks (which
included the heart and surrounding structures) from each group to determine the
presence of any macro or microscopic metastatic tumor deposits. In concordance
with macroscopic findings, clear tumor nodules were noted in control lungs while
no melanoma deposits were seen in any of the other treatment groups (Figure 415B). In control mice, tumor occupied ~61% (4.5%) of the total lung volume
(Figure 4-15C). These results highlight the capacity of long-term expanded Th17
cells to eradicate tumors and provide durable protection from tumor metastasis.

Human Th17-polarized, but not Th1-polarized cells retain antitumor activity
after expansion
As an important step towards translation of this work to clinical trials, we
sought to determine if human Th17 cells possess the same undiminished capacity
to clear tumors after long-term expansion as murine Th17 cells. We expected that
human Th17 cells would remain highly therapeutic while Th1 cells would decline
in efficacy after expansion, similar to our observation with murine Th17 versus Th1
cells. To examine function, phenotype and antitumor efficacy of human Th17 and
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Th1 cells, human CD4+ T cells from the peripheral blood of normal donors were
polarized to either a Th17 or Th1 phenotype. These two subsets were then
expanded for ~2 weeks after activation with anti-CD3 beads coated with ICOS and
CD28, and redirected to express a chimeric antigen receptor that recognizes
mesothelin and signals CD3 and 4-1BB (MesoCAR). We also expanded bulk
CD8+ T cells with CD3/CD28/ICOS beads and IL-2, and engineered them with the
same MesoCAR construct. During expansion, Th17 cells became more polyfunctional with increased capacity to secrete IFN and IL17A (Figure 4-16A).
Interestingly, at all time points human Th17-polarized cells secreted more IFN
than human Th1-polarized cells. This may be because among the cells derived
from the peripheral blood were mature T cells which may have had prior functional
profiles before polarization compared to the mainly naïve T cells from TRP-1
mouse spleens.
However, Th17 polarization did induce high expression of the Th17associated CCR6 chemokine which was largely absent on Th1-polarized cells
(Figure 4-16B), and both Th1 and Th17 cells both expressed similar levels of
CXCR3, a chemokine receptor associated with Th1 cells. Thus, a large portion of
Th17 cells became double positive for CCR6 and CXCR3 by the end of culture, a
phenotypic marker of a highly functional non-classical Th17/Th1 hybrid cell (Figure
4-16B) (188). Additionally, Th17 cells with the highest CCR6 expression also
expressed CCR5 and CCR10, two chemokine receptors important for trafficking to
inflamed tissues (189, 190) (Figure 4-17A-B). While present, these chemokines
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Figure 4-16. Human CD4+ T cells polarized to Th17 cells exhibit increasing
polyfunctionality during ex vivo expansion.

(A) IL-17A and IFN expression by human Th17 and Th1 polarized cells
expanded for 3, 6, 9, or 12 days in vitro, representative of 2 normal donors. (B)
CCR6 and CXCR3 expression on human Th17 and Th1 polarized cells
expanded for 3, 6, 9, or 12 days in vitro, representative of 2 normal donors.
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Figure 4-17. Th17 cells display a wide array of receptors for inflammatory
chemokines and higher effector memory frequencies ex vivo than Th1 cells.

(A) CCR6 and CCR5 expression by human Th17 and Th1 cells expanded for 3,
6, 9, or 12 days in vitro, representative of 2 normal donors. (B) CCR6 and
CCR10 expression on human Th17 and Th1 cells expanded for 3, 6, 9, or 12
days in vitro, representative of 2 normal donors. (C) CD62L against CD4
expression on human Th17 and Th1 cells expanded for 3, 6, 9, or 12 days in
vitro, representative of 2 normal donors.
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were at lower concentrations on Th1 cells. Human Th17 and Th1 cells also showed
a similar memory marker pattern with murine T cells as human Th1 cells expressed
more CD62L at the beginning of culture than human Th17 cells (Figure 4-17C).
However, by day twelve, both subsets had less CD62L expression indicating a
progressive shift to an effector memory phenotype (Figure 4-17C).
To test whether human Th17-polarized cells preserved antitumor activity
during ex vivo expansion, we infused seven or twelve day expanded
MesoCAR+Th17 cells (2e6/mouse) with twelve day expanded MesoCAR+CD8+ T
cells (2e6/mouse) into NSG mice with established M108 mesothelioma tumors. As
a control, we also treated mice with seven or twelve day expanded MesoCAR+Th1
cells (2e6/mouse) with twelve day expanded MesoCAR+CD8+ T cells (2e6/mouse).
We found that MesoCAR+Th17 cells eradicated human mesothelioma regardless
of expansion time (Figure 4-18A). Conversely, treatment with twelve day expanded
CAR+Th1 mediated poor antitumor activity compared to treatment with seven day
expanded CAR+Th1 cells (Figure 4-18A). Importantly, Th17 cells could not mediate
tumor immunity if engineered with a CAR against CD19 (Figure 4-18B). This is not
surprising as mesothelioma tumor do not express CD19 antigen. Also, we tested
the benefit of antigen specific mesoCAR+CD8+ T cells in our human model by cotransferring mesoCAR+Th17 cells with CD19CAR+ CD8+ T cells. While antigen
specific Th17 cells with CD19CAR+CD8+ T cells controlled tumor growth well (and
better than mesoCAR+CD8+ T cells transferred with CD19CAR+Th17 cells), we
only observed curative responses when both the Th17 cells and CD8+ T cells were
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antigen specific against the correct target, mesothelin (Figure 4-18B). Collectively,
our data reveal that human Th17 cells retain their antitumor capacity when
expanded long-term ex vivo. Our human study confirms our findings that durable
Th17 cells generated from ex vivo expansion which dramatically eliminated large
and metastatic melanoma tumors in mice, translates to human T cells with major
implications for improving ACT clinical trials.
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Figure 4-18. Human Th17 cells retain antitumor efficacy after two weeks of ex
vivo expansion while Th1 cells do not.
6

(A) M108 tumor burden of NSG mice treated with 2e 7 or 12 day expanded
+
+
6
mesoCAR Th17 or mesoCAR Th1 cells with 2e 12 day expanded
+
+
mesoCAR CD8 T cells, compared to no treatment; n=8-11 mice/group. (B)
6
+
+
M108 tumor burden of NSG mice treated with 2e CD19CAR or MesoCAR 12
+
day expanded Th17 and CD8 T cells, compared to no treatment; n=6-11
mice/group.
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Discussion
ACT therapy mediates objective response rates in ~50% of cancer patients.
This therapy relies on the infusion of large numbers of T cells (1011) to achieve this
goal. Although CD8+ T cells are often used for ACT, they lose efficacy as they
expand ex vivo. Herein, we discovered that Th17 cells have an undiminished
capacity to regress tumors as they expand. Transferring 2e6 Th17 cells expanded
for 3 weeks ex vivo mediated similar antitumor immunity in mice as infusing 2e 6
“younger” Th17 cells expanded for one week. In contrast, neither Th1 nor CD8+ T
cells retained antitumor efficacy after only two week’s expansion. Thus, on a per
cell basis, the antitumor capacity of Th17 cells is more effective than Th1 or CD8 +
T cells after long-term ex vivo expansion.
We hypothesized that the retention of antitumor efficacy by Th17 cells,
coupled with their expansion to large numbers over 3 weeks would allow us to treat
large recalcitrant melanoma tumors (~175mm2) by treating mice using the entire
cell product. Indeed, this high dose Th17 therapy eradicated tumors in mice and
mediated curative responses for more than 6 months. Also, our cured animals
were protected from a subsequent tumor re-challenge both subcutaneously and
intravenously to model aggressive lung metastases. In contrast, the few Th17 cells
expanded for only one week were insufficient to clear even primary tumors. To our
knowledge, this is the first report that investigates concomitantly 4 factors critical
for ACT: 1) T cell age, 2) T cell yield, 3) T cell subset and 4) level of tumor burden.
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Our findings are relevant as they provide key insight into the potency of Th17 cells,
which expand robustly without diminishing in quality.
We and other investigators have reported beneficial traits of Th17 cells for
ACT (85, 88, 93). Unlike Th1 cells, Th17 cells do not express KLRG1 or TIM3
during expansion while cytokine receptors and costimulatory molecules are more
abundant on Th17 cells than Th1 cells. Moreover, although resistance to apoptosis
in Th17 cells has been reported (88, 191), we provide evidence that their
resistance to apoptosis is continuous throughout in vitro culture. We suspect that
these attributes also permit Th17 cells to persist in the harsh tumor
microenvironment.
Effector memory CD8+ T cells (CD62L-) are far less effective at regressing
tumors when infused into mice or humans compared to their less differentiated
counterparts, such as stem and central memory CD8 + T cells (46, 47, 60). This
observation begs the question: how can early or late effector memory Th17 cells
that express nominal CD62L persist and still regress tumors in vivo? While
previous studies indicate Th17 cells have active -catenin signaling after short in
vitro expansion (85), our western blot analysis of tumor-reactive Th17 cells found
the transcription factor Tcf7 present in the nucleus at all time-points during
expansion. This observation is insightful, as Tcf7 is an essential protein in the
Wnt/-catenin pathway critical for stem memory T cell self-renewal and very
recently found to be critical for formation of memory daughter cells through
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asymmetric T cell division (85, 183). Therefore, we posit that constitutive Tcf7
signaling may partially explain why Th17 cells expand robustly in a petri dish and
persist long-term in vivo. This finding might also explain why Th17 cells maintain
their telomere length in vitro and in vivo, a property directly associated with T cell
persistence in patients with enhanced survival in ACT trials (53-55).
We found Th17 cells are capable of directly lysing tumors. Both early and
late-expanded donor Th17 cells regressed melanoma independent of host CD8 + T
cells, as antibody depletion of CD8+ T cells did not compromise treatment
outcome. This is in alignment with a report by the Antony lab (99) that found tumorreactive CD4+ T cells clear tumor in a class-II-restricted manner in vivo. However,
in our human CAR model, we found that infusion of both antigen specific Th17
cells and CD8+ T cells was needed to mediate optimal antitumor responses, as
MesoCAR+Th17 cells were unable to eradicate the tumors when co-infused with
non-specific CD8 T cells (i.e. CD19CAR+CD8+ T cells) (Figure 4-18B). This finding
agrees with a study by the Dong laboratory (97) which found that depletion of
endogenous CD8+ T cells diminished the antitumor response of Th17 cells, though
it did not abrogate it completely. It is also important to appreciate that a possible
confounding variable of depleting host CD8+ T cells in our TRP ACT melanoma
model would be the creation of space for the donor Th17 cells to engraft and better
consume homeostatic cytokines (82, 138). Collectively, our data support a
multilateral model where donor Th17 cells directly lyse tumor as well as cooperate

114

with other immune cells, such as CD8+ T cells, to protect the host from tumor
relapse long-term.
Based on recent evidence supporting the benefit of shorter preparation time
for ACT cell products (46, 192), cancer immunotherapists are devoting significant
effort to reduce T cell expansion time ex vivo before infusion. A clinical trial at the
NCI reported that they could generate “young TILs” that could mediate improved
regression of metastatic melanoma. Yet, these TIL products were still expanded
for a month ex vivo before return to the patient (87). Additionally, it is important to
note that many parameters besides time contribute to CD8+ T cell exhaustion/loss
of efficacy including: the number of times the T cells are re-stimulated, the growth
factor cytokines used (IL-2 vs. IL-15 vs. IL-21) and the type of co-stimulatory
signals (CD28, ICOS or 41BB) delivered to expand the cells, which can alter their
bioenergetics (43, 48, 69, 76, 94, 107). In particular, IL-2 is the staple growth factor
used to expand TIL and CAR-T cells for ACT. But, while this cytokine has potent
effect on proliferation, IL-2 also differentiates CD8+ T cells to an effector or terminal
status (67). These considerations give further credence to the use of T cells with
stemness, such as Th17 cells or pharmacologically altered CD8+ T cells (60, 85,
120, 121) both of which expand long-term without reaching terminal differentiation.
Of clinical importance, human CAR+Th17-polarized cells also retain their
antitumor potency after long-term expansion while human CAR+Th1-polarized
cells do not. The antitumor activity of human CAR+Th17 cells in our mouse
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xenograft model of mesothelioma were superior to that of CAR +Th1 after either
seven or twelve days of ex vivo expansion. These findings recapitulate those in
our TRP-1 melanoma model where murine Th17 cells mediate greater tumor
immunity than TRP-1 Th1 cells. Of note, while the shortest reported TIL expansion
protocols still require one month of ex vivo expansion, our data with 12-day
expanded human Th17 CD4+ T cells are particularly relevant in the context of CAR
therapies where many T cells can be quickly generated from peripheral blood
within one or two weeks post-apheresis.
In closing, Th17 cells offer promise for next generation ACT trials, as they
can: 1) expand rapidly in vitro for three weeks without requiring re-activation, 2) repopulate the host after infusion regardless of ex vivo expansion time and 3)
mediate potent destruction of large tumors when the total number of cells
generated after 2 or more weeks of ex vivo culture is used. Th17 cell durability may
also result in more consistent success in generating a therapeutic cell product, due
to a larger window of opportunity for securing potent T cells after ex vivo expansion.
The resilience of Th17 cells in vitro may also simplify clinical preparation rendering
them more feasible to prepare for clinical trials in many cancer centers around the
world, thereby extending ACT treatment to a wider patient population.
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Chapter 5: PI3K inhibition fortifies tumor-reactive murine and human CD8+
T cells with durable TCF7+ memory

Introduction
Adoptive cell therapy (ACT) for cancer allows for the enrichment of T cells
optimally suited to exert antitumor immunity. When these T cells express a less
differentiated memory phenotype with high levels of the lymphoid homing
molecules CD62L and CCR7, they induce high rates of objective responses and
long-term survival (50, 62). Conversely, preclinical murine models of ACT indicate
that not only are fully differentiated effector CD8 + T cells ineffective at clearing
tumors (46), but having effector cells within the cell product corrupts the antitumor
potential of the entire population (192). The improved antitumor efficacy of less
differentiated T cells is due in part to an improved capacity to engraft and persist
long-term in the host. This may be due not only to improved trafficking to lymphoid
tissues, but also improved capacity to respond to homeostatic cytokines (73).
Additionally, stem memory T cells (Tscm) which are the least differentiated of the
memory subsets and express active Wnt/-catenin signaling, show the greatest
capacity to clear tumors and provide long-term immunity (60).
Thus, a major pursuit in the ACT field is to select and preferentially expand
T cells in a less differentiated state. Particularly exciting are methods which
pharmaceutically enhance T cell memory during ex vivo expansion. Multiple
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strategies have emerged including blockade of -catenin degradation (60),
increasing/strengthening mitochondrial networks to mimic those seen in memory
T cells (107), denial of glucose via a small molecule inhibitor (103) or inhibition of
the PI3K/AKT axis (120, 121).
The PI3K/AKT axis plays an integral role in T cell activation downstream the
TCR and is important for clonal expansion and cytokine production (110). It also is
involved in memory formation, as AKT phosphorylates and sequesters FOXO
transcription factors preventing transcription of CD62L, CCR7, CD127 and other
molecules associated with less differentiated T cells (193). Patients who have an
overactive PI3K also show rapid proliferation and terminal differentiation of their
CD8+ T cells with resultant chronic inflammation and susceptibility to viral infection
(114, 115). Additionally, murine models which knock out the main kinase subunit
of PI3K in lymphocytes (P110), show reduced proliferation and weak cytokine
production by CD8+ T cells in viral infection (116, 118). While memory formation in
these models was intact, the low numbers of memory T cells formed after primary
infection led to an impaired memory response during a secondary challenge (117,
119).
Yet, in contrast to the weak CD8+ T cell immunity in P110 knockout T cells,
T cells which are treated with a small molecule inhibitor of AKT exert stronger
antitumor responses in both GVL and melanoma (120, 121). These studies
indicate that genetic ablation and pharmaceutical inhibition of PI3K signaling do
not induce the same physiology. Additionally, while signaling through PI3K and
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AKT is often considered the same, PI3K interacts with multiple other kinases
besides AKT including MAPK and PKC kinases (122-124), as well as other AGC
family kinases through the downstream kinase PDK1 (125). Thus, we
hypothesized that pharmaceutical inhibition of p110 will endow tumor-reactive T
cells with a more potent memory phenotype than direct AKT inhibition.
We tested our hypothesis in both murine transgenic TCR pmel-1 T cells and
human peripheral blood CD3+ T cells. These cells were treated with either the
P110 inhibitor CAL-101, or the AKT1/2 inhibitor AKT VIII (AKTi). We found that in
both murine and human T cells CAL-101 induced memory marker expression of
CD62L and CCR7 similarly to AKT. CAL-101 also induced the alpha receptor for
IL-7 (CD127) to a much greater extent than AKTi suggesting these cells might
engraft better in the hosts than even AKTi treated cells (73). Indeed, CAL-101
treated T cells had the highest levels of circulating as well as tumor infiltrating
donor cells which corresponded with improved tumor control and lengthened
survival. Interestingly, PI3K blockade upregulated activity of -catenin greater
than AKTi as shown by increased levels of Tcf7 in the CAL-101 treated cells.
Interestingly, when we tested the importance of CD62L expression and CD127
expression to the antitumor potency of CAL-101 primed T cells, we discovered that
sorting CD62L from IL-2 expanded conventional tumor-reactive T cells could not
recapitulate the potency of CAL-101 priming. Additionally, depletion of IL-7 did not
abrogate the capacity of CAL-101 primed T cells to clear tumor. These results
indicate that the simple application of CAL-101 in the preparation of tumor-reactive
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T cells may provide a distinctly potent cellular product for ACT with improved
capacity to control malignancies.

Pharmaceutical inhibition of p110 in pmel-1 CD8+ T cells increases both
CD62L and CD127 expression without hindering expansion
To test whether PI3K inhibition enhanced the antitumor capacity of tumorreactive T cells compared to direct AKT inhibition, CD8 + T cells from pmel-1
transgenic mice (CD8+ T cells with a transgenic TCR specific for the
melanoma/melanocyte antigen gp100) were activated with their specific antigen
and treated with vehicle control, AKTi as previously published (121), or CAL-101
throughout culture (see methods). As expected, drug treatment induced marked
differences in memory. While 65% of vehicle treated CD8+ T cells expressed
CD62L, nearly all cells treated with AKTi or CAL-101 expressed CD62L (97% and
100% respectively, see Figure 5-01A). Interestingly, the MFI of CD62L on CAL101 treated T cells was higher than on those treated with AKTi. While both drug
treatments lowered the activation marker CD69, CAL-101 had a much stronger
effect on diminishing the MFI of CD44 (Figure 5-01B). While this CD44loCD62Lhi
phenotype mimicked the phenotype of antigen naïve T cells, CAL-101 treated cells
expanded to similar levels as both vehicle and AKTi treated cells. This suggests
that despite PI3K inhibition, T cell receptor and downstream proliferative signaling
were intact (Figure 5-01C).

120

Figure 5-01. CAL-101 priming supports a de-differentiated memory phenotype
+
including high IL-7R expression on pmel-1 CD8 T cells.
+

(A) Representative flow plots of CD44 by CD62L expression on pmel-1 CD8 T
cells primed with vehicle, AKTi or CAL-101 after 5 days of culture; representative
+
of 3 independent cultures. (B) MFI of CD62L, CD69 and CD44 on pmel-1 CD8
T cells after 5 days of culture; n=3 independent cultures. One way repeated
measures ANOVA; ** = p<0.01, *** = p<0.001, **** = p<0.0001. (C) Fold growth
+
and fold increase of pmel-1 CD8 T cells primed with vehicle (DMSO), AKTi, or
CAL-101 5 days following antigen stimulation; n=3 independent cultures. (D)
+
MFI of CD25 and CD127 on pmel-1 CD8 T cells after 5 days of culture; n=3
independent cultures. One way repeated measures ANOVA; ns = not
statistically significant, *** = p<0.001, **** = p<0.0001.
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CD8+ T cells denied PI3K signaling via CAL-101 engraft at higher levels in
vivo and maintain CD62L and CD127 expression
While both drugs slightly lowered CD25 (IL-2 receptor alpha) on T cells in
vitro, they substantially elevated CD127, the alpha receptor for IL-7 (Figure 5-01D).
Signaling through this receptor is important for sustaining naïve and central
memory T cells (72), and supports high numbers of donor cells in the host (73).
We therefore hypothesized that both drug treatments would improve the
engraftment of donor cells and subsequent antitumor immunity. Interestingly, one
week post-treatment, we found that only CAL-101 treatment profoundly increased
donor frequency in the blood. Additionally, while both AKTi and CAL-101 increased
CD62L expression in vitro, only CAL-101 treated T cells retained significantly more
CD44hiCD62Lhi and fewer CD44hiCD62Llo circulating cells compared to the other
treatments (Figure 5-02A). Additionally, while both AKTi and CAL-101 had fewer
PD1+ donor cells, only CAL-101 reduced the frequency of donor cells expressing
the exhaustion marker KLRG1 (Figure 5-02A). CAL-101 treated CD8+ T cells also
retained a far larger portion of CD127+ T cells than the other groups (Figure 502A). CAL-101 donor T cells were similarly found at higher levels than AKTi and
vehicle donor cells within the spleen and draining (inguinal) lymph nodes of the
mice (not shown).
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Figure 5-02. CAL-101 primed T cells preserve dedifferentiated phenotype in vivo
and persist at higher numbers.

(A-B) Frequency of donor pmel-1 T cells and extracellular markers on pmel-1
donor T cells in (A) blood and (B) tumor 7 days following treatment; n=3
mice/group. One way repeated measures ANOVA; ns = not statistically
significant, * = p<0.05, ** = p<0.01, *** = p<0.001.
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T cells treated with CAL-101 effectively infiltrate the tumor, arresting tumor
growth and prolonging survival
We expected that the retention of a less differentiated memory phenotype
and high CD127 by CAL-101 treated cells in circulation would translate to higher
donor cell numbers in the tumor and therefore, improved antitumor immunity.
Again, we observed a higher frequency of CAL-101 treated T cells in the tumor
compared to control treated T cells. Surprisingly, there were also more central
memory CAL-101 treated cells in the tumor. However, percentage of PD1 + and
KLRG1+ donor cells in the tumor were similar between groups (Figure 5-02B). Yet,
CAL-101 cells slowed the growth of B16F10 melanoma in mice (Figure 5-03A-B),
This extending the survival of animals infused with CAL-101 treated T cells (Figure
5-03C).
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Figure 5-03. CAL-101 primed pmel-1 CD8+ T cells exert stronger antitumor
response against B16F10 tumors.
2

(A) Tumor burden (mm ) of individual mice which received no T cell treatment,
5
+
or 8 x 10 pmel-1 CD8 T cells primed with vehicle, AKTi, or CAL-101; n=10-12
2
mice/group. (B) Average tumor burden (mm ) of treatment groups; n=10-12
mice/group. (C) Percent survival of above treatment groups; n=10-12
mice/group. Kaplan Meier curve analyzed by log rank test; **** = p<0.0001.
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CAL-101 induces Tcf7 signaling in human central memory T cells
We next determined if pharmaceutically inhibiting PI3K would also
augment the fitness and memory properties of human T cells. To address this
question, we similarly treated human CD3+ T cells isolated from peripheral blood
mononuclear cells of healthy donors with CAL-101 and expanded them with
CD3/CD28 beads. We found that CAL-101 treated cells had slightly lower levels
of CD45RO, a marker of T cell maturation, and the highest CCR7 (Figure 5-04AB). PD1 was nominally expressed on all groups, however both PI3K and AKT
blockade prevented upregulation of TIM3 post-activation compared to untreated T
cells (Figure 5-04C). PI3K blockade with CAL-101 had little impact on CD25 but
greatly increased CD127 on T cells (Figure 5-04C-D).
Given that T cells treated with CAL-101 were effective in preventing the
growth of melanoma long term, we suspected that PI3K signaling bolsters
stemness. To determine if PI3K blockade induced Wnt/-catenin signaling in T
cells, we assayed the levels of nuclear -catenin and the downstream transcription
factors Lef1 and Tcf7. While nuclear -catenin was similar between groups, drug
primed T cells evidenced increased transcriptional activity by -catenin as
indicated by slightly higher Lef1. However, PI3K blockade uniquely increased
nuclear Tcf7 to significant levels (Figure 5-05A-B). Thus, while the phenotype of
AKT inhibited T cells resembles that of potent central memory T cells,
PI3Kblockade induces a stem memory phenotype in T cells known to exert an
even stronger antitumor response (60).
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Figure 5-04. PI3K blockade induces central memory phenotype in human
+
polyclonal CD3 T cells similar to AKTi.

(A) CD44 and CD62L expression on vehicle, AKTi, or CAL-101 treated T cells;
representative of 9 donors. (B) MFI of CD45RO, CD62L and CCR7 on human
+
CD3 T cells sorted from peripheral blood; n=9 normal donors. One way
+
repeated measures ANOVA; * = p<0.05. (C) Frequency of human CD3 T cells
expressing PD1, TIM3, CD25 and CD127; n=9 normal donors. One way
repeated measures ANOVA; ** = p<0.01. (D) Histogram of CD127 expression
on vehicle, AKTi, or CAL-101 treated T cells compared to no stain with frequency
of positive cells indicated next to legend; representative of 9 donors.
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Figure 5-05. PI3K blockade upregulates Tcf7 in human polyclonal CD3 T cells.

(A) Western blot of nuclear protein extracts from vehicle, AKTi, or CAL-101
treated T cells, B = -catenin, L = Lef1, T = Tcf7, H = Histone H3; representative
of 4-6 donors. (B) Quantified protein levels relative to Histone H3, RROD GOI/H
= relative ratio of optical density (gene of interest over Histone H3); n=4 -6
normal donors. One way repeated measures ANOVA; ns = not statistically
significant, * = p<0.05.
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PI3Kblockade augments the antitumor activity of human CAR-T cells
Based on the stem memory phenotype of CAL-101 primed human T cells,
we hypothesized that treating a human tumor with CAL-101 primed CAR-T cells
would improve antitumor control over treatment with AKT inhibited T cells. To
address this idea, we transduced human T cells with a lentiviral vector containing
the 4-1BBzeta anti-mesothelin CAR (38), expanded them for seven days with IL-2
or treated with AKTi or CAL-101, and transferred them into mice bearing
subcutaneous mesothelioma. While all treatment groups reduced tumor burden in
the mice (Figure 5-06A), only CAL-101 treated mice remained in remission from
baseline after 51 days of treatment (Figure 5-06B-C). Thus, CAL-101 priming of T
cells for ACT may provide more consistent antitumor responses for patients with
less chance of tumor progression.
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Figure 5-06. CAL-101 primed mesoCAR-T cells exert stronger antitumor
immunity.

(A) NSG mice with M108 given subcutaneously 51 days prior were treated with
5
+
4 x 10 CD3 mesoCAR-T cells primed with vehicle, AKTi, or CAL-101; n=8-12
mice/group. (B) Percent change in size of tumors 71 days post-treatment
compared to baseline tumor measurement at time of treatment; n=8-12
mice/group. (C) Tumor weight at day 71 post-transfer; n=8-12 mice/group. (D)
+
Frequency of human CD45 lymphocytes within the blood of treated mice 55
days post-transfer; n=2-12 mice/group. One way repeated measures ANOVA;
ns = not statistically significant, * = p<0.05.
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Antitumor potency induced by PI3K inhibition is not due to CD62L
CD62L expression on T cells correlates with improved antitumor immunity
in pre-clinical ACT tumor models (46-48, 50, 192) and enriching central memory T
cells from peripheral blood and redirecting them with a CD19 specific CAR has
shown efficacy in an early clinical trial (62). Additionally, our studies corroborated
these data showing a correlation between retained CD62L expression in vivo by
CAL-101 treated donor cells and prolonged tumor control (Figure 5-02 and 5-03).
Thus, we hypothesized that CD62L expression is responsible for a successful
memory immune response against cancer. To better clarify the role of CD62L in
tumor immunity, we sorted CD62L+ T cells from vehicle treated pmel-1 T cells and
compared their antitumor impact against B16F10 to bulk vehicle T cells (which
were 48% CD62L+) and CAL-101 treated T cells (which were 100% CD62L+, see
Figure 5-07A). We suspected that both the CD62L+ vehicle group and CAL-101
group would exert similar tumor control given they possess a central memory
phenotype. But surprisingly, sort CD62L+ pmel-1 cells from vehicle cultures did not
improve treatment outcome over therapy with bulk vehicle. In contrast, CAL-101
mediated prolonged antitumor control (Figure 5-07B) and better survival (Figure 507C) in mice. Thus, while T cells capable of long-lived memory responses against
tumor do express CD62L, enriching cells after ex vivo expansion that express this
molecule does not appear to be sufficient to drive a successful antitumor response.
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Figure 5-07. The antitumor potency of CAL-101 primed T cells is CD62L
independent.

(A) Post-sort analysis of CD62L expression against V13 on pmel-1 T
+
cells. sorted by fluorescence activated cell sorting as CD62L , or T cells treated
5
with CAL-101. (B) Mice with B16F10 were treated with 8x10 bulk vehicle,
+
CD62L vehicle or CAL-101 pmel-1 cells compared to no treatment; n=7
mice/group. (C) Percent survival of mice treated with vehicle primed T cells,
+
vehicle primed CD62L T cells, or CAL-101 primed T cells; n=7 mice/group.
Kaplan Meier curve analyzed by log rank test; *** = p<0.001.
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The efficacy of PI3K blockade T cell therapy is independent of IL-7
signaling
PI3K blockade induced CD127 on murine T cells in vitro. Moreover, CD127
was sustained on CAL-101 treated T cells after transfer (Figure 1D-E). This drug
also induced high CD127 on human peripheral CD3+ T cells Figure 3C-D). We
therefore posited that CAL-101 T cells thrived in vivo due to their enhanced
responsiveness to IL-7. Thus, we tested the importance of IL-7 in the pmel-1
B16F10 model by depleting IL-7 for the first two weeks after transfer, as previously
published (73). We suspected that depleting IL-7 would decrease engraftment of
the donor cells and impair their control of the tumor. In contrast, we found that
while CAL-101 primed T cells engrafted at significantly higher numbers than
vehicle or AKTi treated T cells in both isotype and IL-7 depleted mice, there was
no significant difference between the CAL-101 treatment groups in frequency or
memory phenotype (Figure 5-08A-B). CAL-101 primed T cells also exerted their
prolonged antitumor immunity whether IL-7 had been depleted or not (Figure 509A) which resulted in no differences in survival between the CAL-101 T cell
groups (Figure 5-09B).
Thus, based on these data, the antitumor capacity and engraftment of CAL101 primed T cells appears to be IL-7 independent. However, it is probable that
the administration of the anti-IL-7 antibody was insufficient to deplete IL-7 and that
the higher expression of CD127 on the CAL-101 primed T cells allowed for
successful scavenging of this cytokine. Additionally, we administered IL-2 complex
in this experiment as was performed in the other experiments. This may have
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compensated for IL-7, though the mechanisms of these two cytokines are not
redundant (65). Future studies using T cells from Il7r conditional knockout mice
may determine the importance of CD127 to the longevity of CAL-101 primed T
cell antitumor response.
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Figure 5-08. Depletion of IL-7 does not alter numbers or memory phenotype of
donor CAL-101 T cells.

(A-B) Analysis of in vivo numbers and memory phenotype of transferred pmel1 T cells primed with vehicle, AKTi, or CAL-101 10 days after transfer into (A)
isotype or (B) IL-7 depleted mice; n=5 mice/group. One way repeated measures
ANOVA; ns = not statistically significant, * = p<0.05, ** = p<0.01, *** = p<0.001,
**** = p<0.0001.
135

Figure 5-09. The antitumor potency of CAL-101 primed T cells is CD127
independent.

(A) Individual tumor burden of isotype or IL-7 depleted mice receiving vehicle,
AKTi, or CAL-101 primed donor cells; n=10 mice/group. (B) Percent survival of
mice in panel A; n=10 mice/group. Kaplan Meier curve analyzed by log rank
test; ns = not statistically significant, ** = p<0.01. (C) Percent specific lysis of
hgp100 loaded splenocytes by CAL-101 primed pmel-1 T cells in isotype treated
or IL-7 depleted mice 53 days post-transfer; n=6-7 mice/group; ns = not
statistically significant.
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Discussion
Collectively, our data indicate that while PI3K is upstream of AKT, its
blockade through inhibition of p110 induces stronger memory in CD8+ T cells than
AKT inhibition. Furthermore, while inhibition of either PI3K or AKT supports the
generation of central memory T cells, we found that PI3K blockade preferentially
increases CD127 and the stem memory transcription factor Tcf7. Additionally,
PI3K blockade improved the antitumor response of both murine and human
tumor-reactive T cells over that of traditionally expanded (vehicle) or AKTi-treated
T cells. We set out to determine if CD62L and CD127 were responsible for the
enhanced antitumor immunity of CAL-101 memory T cells. Our studies offer early
evidence that the longevity of immune responses exerted by memory T cells
cannot be explained by CD62L or CD127 expression alone. This was evidenced
by the poorer antitumor immunity of sorted CD62L+ T cells from vehicle expanded
T cells compared to CAL-101 primed T cells. Additionally, in vivo blockade of IL-7
was insufficient to impair the antitumor efficacy of CAL-101 primed T cells.
Successful immunity against both viral infections and cancer requires longterm protection provided by memory cells (52). We have classically associated T
cell memory with expression of surface markers such as CD62L, CCR7 and
CD127 (58, 72), which were increased in both AKTi and CAL-101 treated T cells.
Thus both P110 and AKT inhibition seem to prevent phosphorylation of FOXO
transcription factors by AKT (193) as we expected. However, the level of these
receptors was different between PI3K and AKT blockade, as well as the resultant
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antitumor response, indicating that other pathways were being altered uniquely by
CAL-101 treatment. One pathway which is consistently associated with durable
memory T cells is the Wnt/-catenin pathway, whether it be active in stem memory
T cells (60, 64) or in Th17 cells (85). We found that CAL-101 increased Tcf7
expression in human T cells significantly above vehicle while AKTi inhibition did
not. As the Wnt/-catenin pathway interacts with FOXO transcription (194, 195),
this may explain why receptors such as CD62L, CCR7 and CD127 were higher in
these cells. However, as PI3K blockade augmented antitumor potency in an
apparent CD62L and IL-7 independent manner, we suspect that the contribution
of Tcf7 to the memory of T cells cannot be described solely by potentiation of
FOXO derived memory. Thus, future studies with Tcf7 knockout T cells will help
us understand the role and mechanism of Tcf7 in enhancing memory due to PI3K
blockade.
Among the class 1A catalytic subunits of PI3K, P110is expressed mainly
in the hematopoietic lineage (196) while P110, and  are thought to play a
minimal role (108, 109). This corroborates with early studies in our lab using
specific inhibitors of the other subunits which did not generate T cells with the same
antitumor potency as P110 blockade (not shown). Yet, while CAL-101 treatment’s
potentiation of T cell memory appears to be unique to P110 blockade, CAL-101
also has reported effects on the class II, III and IV PI3Kinases when used at doses
similar to what we used to treat our T cells (197). Therefore, the effects on T cells
mediated by CAL-101 may not be due entirely to P110 blockade. Future
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experiments with P110 knockout mice with or without CAL-101 treatment will
further elucidate the way in which CAL-101 primes T cells to exert more powerful
antitumor immunity.
Inducing a durable memory phenotype through reversible pharmaceutical
manipulation of PI3K is an attractive way of generating potent memory T cells.
Yet, while CAL-101 T cells exerted a longer antitumor response than vehicle and
AKTi treated T cells, they eventually lost control of the tumor in most mice (Figure
2B). We found that as early as one week after transfer, these cells were expressing
similar levels of PD-1 and KLRG-1 compared to vehicle and AKTi treated T cells
(Figure 2A). Thus, while PI3K blockade induces a strong memory phenotype
including high Tcf7 expression, it does not appear to protect the cells from
inhibitory signaling and exhaustion. We posit that a combination of PD-1
checkpoint blockade therapy may prevent the reestablishment of immune
tolerance observed in donor CAL-101 cells and allow for continued tumor control.
Additionally, while we demonstrate the power of ex vivo priming with CAL101 to enhance the antitumor function of T cells, we recognize that there may be
other viable strategies for employing this drug. It may be especially powerful to add
CAL-101 treatment in combination with extant immunotherapies to boost the
effector function of tumor-reactive T cells. For example, in addition to its capacity
to boost effector T cells, its direct cytotoxic effects on cancers (198) as well as its
ability to break immune tolerance (199) are well known and may synergize well
with checkpoint blockade or vaccine even outside the context of ACT.
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Nonetheless, whatever the route of application may be, we submit the use
of CAL-101 as a viable and potent method for enhancing immune-based therapies
for cancer to improve patient responses and survival.
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Chapter 6: Improving ACT outcomes by amplifying memory in tumorreactive T cells

Summary
For

patients

diagnosed

with

metastatic disease,

the

advent

of

immunotherapy has changed the expectation for the level and frequency of
responses and complete remissions. Adoptive T cell therapy (ACT) for cancer is
one of the most exciting immunotherapies with unprecedented levels of complete
responses in patients who receive this treatment (27). In its simplest form, ACT
involves the procurement, ex vivo selection, and expansion of autologous tumorreactive T cells for reintroduction into a lymphodepleted host. However, we are
finding that each step of this process can impact the T cell’s fitness with marked
impact on the therapeutic outcomes. One fundamental rule emerging from recent
studies is to ensure that the T cells transferred have a memory phenotype capable
of inducing long-term immunity in the patient. Currently, three of the hallmarks of
T cells capable of a long-lived antitumor response: 1) CD62L and/or CCR7
expression, 2) Wnt/-catenin signaling and Tcf7 expression, and 3) high
responsiveness to homeostatic cytokines, especially IL-7. Herein, we examine
how the different elements of ACT effect the memory and resultant antitumor
efficacy of a T cell product. This included investigating: 1) how preconditioning
affects the memory and function of tumor-reactive CD8+ T cell subsets, 2) the
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benefit of using Th17 T cells with durable stem memory and long-lived antitumor
responses, and 3) a pharmaceutical method to induce memory in T cells by
blocking PI3K signaling.
We found that while TBI preconditioning enhances and prolongs the
antitumor efficacy of Tc17 cells more than Tc0 cells. However, this was not due to
enhanced CD62L expression, but rather due to IL-12 induced polyfunctionality
including a stronger cytokine production upon antigen reintroduction. Th17 cells
generated by cytokine polarization of both murine and human CD4+ T cells
expanded to large numbers but retained the capacity to persist long-term and
eradicated tumors. We found evidence of preserved Tcf7 expression in these cells
as well as preserved telomere length, both of which are associated with T cells
which exert strong memory-based immunity. Finally, we found that CAL-101
inhibition of PI3K in both murine, and human tumor-reactive T cells induced a
strong memory phenotype. This included expression of lymphoid homing
receptors, stem signaling and heightened levels of CD127 with enhanced tumor
control compared to vehicle and AKTi treated T cells.
In the setting of PI3K blockade we also tested the contribution of CD62L,
and CD127 to the actual antitumor capacity of T cells. Interestingly, we found that
the potency of CAL-101 treated T cells cannot be explained fully by either CD62L
expression, or IL-7 responsiveness. We now believe that despite the drug’s shortterm and reversible direct effects on PI3K, it is inducing stable genetic
reprogramming that results in a durable and distinct physiology. Studying this
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physiology and the importance of Tcf7 to the antitumor potency of T cells are part
of our future directions.
Taken together, our studies show the importance of careful attention to the
methods of T cell preparation as each part of the protocol has an influence on the
memory and resulting potency of the T cells. We also show that defining effective
memory via traditional ligands and receptors is not as reliable as examining the
genetic memory imprint on those cells via stemness and mitogen signaling. We
offer strong evidence for the use of cells which either naturally exhibit genetic
profiles of stemness such as Th17 cells, or the use of pharmaceutically altered
cells which have these pathways induced. We believe these findings are directly
applicable to the current challenges in ACT including the inherent cost, technical
difficulty and

inconsistency in

generating therapeutic cellular products.

Additionally, our future efforts will better define the ways we can select, generate,
and manipulate potent antitumor T cells.

Future Directions: better understanding how to enhance memory in tumorreactive T cells
Th17 cells have been described as long-lived effectors, and we have
confirmed their ability to retain effector function and exert long-term immunity. Yet,
it is still unclear if these properties are due to Wnt/-catenin signaling or some
other process. While it is likely the case that Tcf7 signaling will be one of a group
of memory related pathways regulated by the Th17 master transcription factor
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RORt, we also saw induction of Tcf7 by blockade of PI3K without RORgt
inducing cytokine polarization. Thus, while it may not fully explain the durability of
Th17 cells or the longevity of CAL-101 induced memory responses, we posit that
it is vital to the memory phenotype we observed in both cell types. Thus, we are
planning future studies using Tcf7 knockout mice which should help elucidate the
importance of this pathway to Th17 and CAL-101 primed T cell phenotype.
Additionally, these cells offer an excellent model system to scrutinize what drives
long-lived memory and effector capacity. We will therefore undertake
transcriptome analysis in these cells to search out novel drivers of T cell memory.
The difference between drug inhibition versus genetic knockout of P110
begs the question of how CAL-101 is inducing the memory phenotype and
antitumor function we see in CAL-101 primed cells. We propose that another
benefit of CAL-101 priming beyond induced memory is prevention of exhaustion
during ex vivo expansion similar to what’s been seen in patients with overactive
PI3K signaling (114, 115). Additionally, while CAL-101 is highly specific for the
delta subunit by industry standards, we use concentrations which likely inhibit other
classes of PI3K (197). We are planning future studies where P110 knockout mice
treated with CAL-101 to see if those T cells can still achieve the memory phenotype
and antitumor potency we see in wild-type mice. We are particularly interested in
looking at epigenetic changes since the memory phenotype induced by CAL-101
appears stable, in that the cells have superior antitumor efficacy long after the drug
has been washed off. We plan on analyzing the epigenetic landscape of drug
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primed cells using the Assay for Transposase Accessible-Chromatin (ATAC)
sequencing to understand how memory is imprinted via drug treatment.
Compared to the T cells used currently in ACT, both Th17 cells and CAL101 primed T cells represent a marked improvement in effector quality and
durability. We have experienced consistency in both ex vivo preparation, which
requires small adjustments to current expansion protocols. Thus, we are motivated
to design clinical trials using these two cell products. In the meantime, we are also
aware of opportunities to use CAL-101 in the original systemic treatment format,
recognizing that its potentiating effects on effector cells may also occur in vivo. We
would conduct these experiments in a phase I type format to try and reduce the
toxicity observed in systemic CAL-101 treatment while preserving its effects on
CD8+ T cell memory. In this vein, combination therapy with CAL-101 and
checkpoint blockade is particularly attractive to combine both effector
enhancement with multiple mechanisms for breaking tolerance in the tumor
microenvironment.
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